nvcr-10q_20160930.htm

0001564590-16-026833.txt : 20161102 0001564590-16-026833.hdr.sgml : 20161102 20161102061623 ACCESSION NUMBER: 0001564590-16-026833 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161102 DATE AS OF CHANGE: 20161102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novocure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 161966234 BUSINESS ADDRESS: STREET 1: LE MASURIER HOUSE, LA RUE LE MASURIER CITY: ST. HELIER STATE: Y9 ZIP: JE2 4YE BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: LE MASURIER HOUSE, LA RUE LE MASURIER CITY: ST. HELIER STATE: Y9 ZIP: JE2 4YE 10-Q 1 nvcr-10q_20160930.htm NVCR-10Q-20160930 nvcr-10q_20160930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-37565

NovoCure Limited

(Exact Name of Registrant as Specified in Its Charter)

Jersey (Channel Islands)		98-1057807
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

Le Masurier House

La Rue Le Masurier

St. Helier, Jersey JE2 4YE

(Address of principal executive offices)

+44 (0) 15 3475 6700

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐			Accelerated filer	☐
Non-accelerated filer	☒		(Do not check if a smaller reporting company)	Smaller reporting company	☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date.

Class		Outstanding as of October 27, 2016
Ordinary shares, no par value		86,780,413 Shares

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

In addition to historical facts or statements of current condition, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements contained in this report are based on our current plans, expectations, hopes, beliefs, intentions or strategies concerning future developments and their impact on us. Forward-looking statements contained in this report constitute our expectations or forecasts of future events as of the date this report was filed with the Securities and Exchange Commission and are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical or current facts. Such statements may include words such as “anticipate,” “will,” “estimate,” “expect,” “project,” “intend,” “should,” “plan,” “believe,” “hope,” and other words and terms of similar meaning in connection with any discussion of, among other things, future operating or financial performance, strategic initiatives and business strategies, regulatory or competitive environments, our intellectual property and delivery system research and development. In particular, these forward-looking statements include, among others, statements about:

•

our research and development, clinical trial and commercialization activities and projected expenditures;

•

the further commercialization of Optune®, our first Tumor Treating Fields (“TTFields”) delivery system, and our other TTFields delivery system candidates;

•

our business strategies and the expansion of our sales and marketing efforts in the United States and in other countries;

•

the market acceptance of Optune and our other TTFields delivery systems by patients, physicians, third-party payers and others in the healthcare and scientific community;

•

our plans to pursue the use of TTFields for the treatment of other solid tumor cancers;

•

our estimates regarding revenues, expenses, capital requirements and needs for additional financing;

•

our ability to obtain regulatory approvals for additional indications and any future TTFields delivery systems;

•

our ability to acquire the supplies needed to manufacture our TTFields delivery systems from third-party suppliers;

•

our ability to manufacture adequate supply;

•

our ability to secure adequate coverage from third-party payers to reimburse us for Optune or future TTFields delivery systems;

•

our ability to maintain and develop our intellectual property position;

•

our cash needs; and

•

our prospects, financial condition and results of operations.

These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in materi al respects from those projected in these forward-looking statements. Factors which may cause such differences to occur include those risks and uncertainties set forth under Part I, Item 1A., “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, as well as other risks and uncertainties set forth from time to time in the reports we file with the U.S. Securities and Exchange Commission. We do not intend to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

TRADEMARKS

This Quarterly Report on Form 10-Q includes trademarks of NovoCure Limited and other persons. All trademarks or trade names referred to herein are the property of their respective owners.

NovoCure Limited

Quarterly Report on Form 10-Q

TABLE OF CONTENTS

		Page
Cautionary Note Regarding Forward Looking Statements		ii
Trademarks		ii


PART I—FINANCIAL INFORMATION

Item 1.	Financial Statements	2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12
Item 4.	Controls and Procedures	20

PART II—OTHER INFORMATION

Item 6.	Exhibits	21

	Signatures	22

- 1 -

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

	September 30,		December 31,
	2016		2015
	Unaudited		Audited
ASSETS

CURRENT ASSETS:
Cash and cash equivalents	$	115,822	$	119,423
Short-term investments		119,724		150,001
Restricted cash		72		87
Receivables and prepaid expenses		11,840		10,799
Inventories		23,972		13,594
Total current assets		271,430		293,904

LONG-TERM ASSETS:
Property and equipment, net		9,886		6,552
Field equipment, net		8,042		6,029
Severance pay fund		89		79
Other long-term assets		1,646		772
Total long-term assets		19,663		13,432

TOTAL ASSETS	$	291,093	$	307,336

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 2 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share data)

	September 30,			December 31,
	2016			2015
	Unaudited			Audited
LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:
Trade payables	$	15,243		$	16,755
Other payables and accrued expenses		14,469			11,872
Total current liabilities		29,712			28,627

LONG-TERM LIABILITIES:
Long-term loan, net of discount and issuance costs		95,970			23,097
Employee benefit liabilities		3,132			2,057
Other long-term liabilities		4,036			2,735
Total long-term liabilities		103,138			27,889

TOTAL LIABILITIES		132,850			56,516

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:
Share capital -
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,775,203 (unaudited) shares and 83,778,581 shares at September 30, 2016 and December 31, 2015, respectively		-			-
Additional paid-in capital		658,086			640,406
Accumulated other comprehensive loss		(2,085	)		(1,505	)
Accumulated deficit		(497,758	)		(388,081	)
Total shareholders' equity		158,243			250,820

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	291,093		$	307,336

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 3 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and per share data)

	Three months ended September 30,						Nine months ended September 30,						Year ended December 31,
	2016			2015			2016			2015			2015
	Unaudited						Unaudited						Audited
Net revenues	$	21,674		$	8,953		$	52,646		$	20,704		$	33,087
Cost of revenues		11,118			5,659			28,897			14,306			20,610
Impairment of field equipment		-			-			6,412			-			-

Gross profit		10,556			3,294			17,337			6,398			12,477

Operating costs and expenses:
Research, development and clinical trials		10,233			10,211			32,996			32,903			43,748
Sales and marketing		15,865			8,916			43,771			24,137			38,861
General and administrative		12,723			8,405			38,010			22,748			33,864

Total operating costs and expenses		38,821			27,532			114,777			79,788			116,473

Operating loss		(28,265	)		(24,238	)		(97,440	)		(73,390	)		(103,996	)
Financial expenses, net		2,189			809			3,293			2,277			3,151

Loss before income tax expense		(30,454	)		(25,047	)		(100,733	)		(75,667	)		(107,147	)
Income tax expense		3,174			976			8,944			2,986			4,434

Net loss	$	(33,628	)	$	(26,023	)	$	(109,677	)	$	(78,653	)	$	(111,581	)

Basic and diluted net loss per ordinary share	$	(0.39	)	$	(2.09	)	$	(1.29	)	$	(6.21	)	$	(3.67	)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share		85,774,874			12,431,586			85,153,644			12,666,455			30,401,603

CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME

U.S. dollars in thousands

	Three months ended September 30,						Nine months ended September 30,						Year ended December 31,
	2016			2015			2016			2015			2015
	Unaudited						Unaudited						Audited
Net loss	$	(33,628	)	$	(26,023	)	$	(109,677	)	$	(78,653	)	$	(111,581	)
Other comprehensive loss, net of tax :
Change in foreign currency translation adjustments		8			-			64			-			-
Pension benefit plan		(409	)		-			(644	)		-			(1,505	)
Total comprehensive loss	$	(34,029	)	$	(26,023	)	$	(110,257	)	$	(78,653	)	$	(113,086	)

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 4 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

U.S. dollars in thousands (except share data)

	Ordinary shares			Preferred shares			Additional paid-in		Accumulated other comprehensive			Accumulated			Total shareholders'
	Shares			Shares			capital		loss			deficit			equity
Balance as of January 1, 2015 (audited)		13,431,414			58,676,017		$	374,375	$	-		$	(276,500	)	$	97,875
Share-based compensation to employees		-			-			11,860		-			-			11,860
Exercise of options and warrants		731,665			-			2,038		-			-			2,038
Issuance of Series J preferred shares, net (a)		-			4,068,500			94,599		-			-			94,599
Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification		(1,005,210	)		-			-		-			-			-
Issuance of ordinary shares upon IPO and exercise of over-allotment, net (b)		7,876,195			-			157,534		-			-			157,534
Conversion of preferred shares to ordinary shares		62,744,517			(62,744,517	)		-		-			-			-
Other comprehensive loss, net of tax benefit		-			-			-		(1,505	)		-			(1,505	)
Net loss		-			-			-		-			(111,581	)		(111,581	)
Balance as of December 31, 2015 (audited)		83,778,581			-			640,406		(1,505	)		(388,081	)		250,820
Share-based compensation to employees		-			-			16,719		-			-			16,719
Exercise of options and warrants		1,996,622			-			961		-			-			961
Other comprehensive loss, net of tax benefit		-			-			-		(580	)		-			(580	)
Net loss		-			-			-		-			(109,677	)		(109,677	)
Balance as of September 30, 2016 (unaudited)		85,775,203			-		$	658,086	$	(2,085	)	$	(497,758	)	$	158,243

(a)	Net of issuance expenses of $319

(b)	Net of issuance expenses (including underwriter fees) of $15,742

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

- 5 -

NOVOCURE LIMITED AND SUBSIDIARIES

CONDENSED INTERIM CONSOLIDATED CASH FLOWS

U.S. dollars in thousands

	Three months ended September 30,						Nine months ended September 30,						Year ended December 31,
	2016			2015			2016			2015			2015
	Unaudited						Unaudited						Audited
Cash flows from operating activities:
Net loss	$	(33,628	)	$	(26,023	)	$	(109,677	)	$	(78,653	)	$	(111,581	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,553			893			4,063			2,005			3,153
Asset write-downs and impairment of field equipment		10			-			6,440			42			46
Increase (decrease) in accrued interest expense		222			(565	)		222			154			672
Share-based compensation to employees		5,626			2,928			16,719			7,372			11,860
Amortization of discount		81			88			25			231			329
Decrease (increase) in receivables and prepaid expenses		694			(1,427	)		(1,514	)		(4,453	)		(5,088	)
Increase in inventories		(2,757	)		(2,556	)		(10,378	)		(7,703	)		(10,148	)
Decrease (increase) in other long-term assets		(526	)		250			(804	)		79			(381	)
Increase (decrease) in trade payables		(6,765	)		1,512			(2,621	)		4,597			6,961
Increase in other payables and accrued expenses		1,651			2,374			2,407			2,892			3,579
Increase (decrease) in employee benefit liabilities, net		80			(10	)		350			(3	)		133
Increase (decrease) in other long-term liabilities		263			430			901			(323	)		581
Net cash used in operating activities	$	(33,496	)	$	(22,106	)	$	(93,867	)	$	(73,763	)	$	(99,884	)

Cash flows from investing activities:
Purchase of property and equipment	$	(1,715	)	$	(1,196	)	$	(5,055	)	$	(3,613	)	$	(4,667	)
Purchase of field equipment		(3,113	)		(1,367	)		(9,213	)		(3,547	)		(5,604	)
Decrease (increase) in restricted cash		27			(72	)		15			(105	)		(26	)
Proceeds from maturity of short-term investments		120,000			30,000			270,000			77,000			104,000
Purchase of short-term investments		(119,613	)		-			(239,341	)		(58,992	)		(208,998	)
Net cash provided by (used in) investing activities	$	(4,414	)	$	27,365		$	16,406		$	10,743		$	(115,295	)

Cash flows from financing activities:
Proceeds from issuance of shares, net	$	-		$	-		$	-		$	94,599		$	252,133
Proceeds from long-term loan, net		72,870			-			72,887			22,886			22,886
Deferred IPO costs		-			(1,439	)		-			(1,733	)		-
Repayment of other long-term loan		(17	)		(16	)		(52	)		(47	)		(63	)
Purchase of shares in respect of settlement		-			-			-			(5	)		(5	)
Exercise of options and warrants		-			12			961			31			2,038
Net cash provided by (used in) financing activities	$	72,853		$	(1,443	)	$	73,796		$	115,731		$	276,989

Effect of exchange rate changes on cash and cash equivalents	$	8		$	-		$	64		$	-		$	-

Increase (decrease) in cash and cash equivalents		34,951			3,816			(3,601	)		52,711			61,810
Cash and cash equivalents at the beginning of the period		80,871			106,508			119,423			57,613			57,613

Cash and cash equivalents at the end of the period	$	115,822		$	110,324		$	115,822		$	110,324		$	119,423

Supplemental cash flow activities:
Cash paid during the period for:
Income taxes	$	4,624		$	658		$	7,793		$	1,683		$	1,489
Interest	$	1,880		$	1,252		$	3,813		$	823		$	1,688

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements

- 6 -

NOVOCURE LIMITED AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except share data)

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION

Organization. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015.

Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements.

Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.

- 7 -

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.

In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

NOTE 2: SHORT-TERM INVESTMENTS

The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,724 and $150,001 as of September 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of September 30, 2016 and December 31, 2015 was $119,604 and $149,978, respectively.

NOTE 3: INVENTORIES

Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:

	September 30,		December 31,
	2016		2015
	Unaudited		Audited
Raw materials	$	4,517	$	3,518
Work in progress		9,621		4,618
Finished products		9,834		5,458
Total	$	23,972	$	13,594

NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES

The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.

As of September 30, 2016 and December 31, 2015, the Company pledged bank deposits of $807 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $962 and $283, respectively.

NOTE 5: SHARE CAPITAL

For the nine months ended September 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644 and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the nine months ended September 30, 2016, options to purchase 825,240 ordinary shares were exercised for cash and options to purchase 3,547 ordinary shares were cashlessly exercised, resulting in the issuance of 825,669 ordinary shares. For additional information on option exercises, please see Note 6.

- 8 -

NOTE 6: EQUITY INCENTIVE PLAN

In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.

The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant.

As of September 30, 2016, 12,717,460 ordinary shares were available for grant under the 2015 Plan.

A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:

	Nine months ended September 30,
	Unaudited
	Number of options			Weighted average exercise price
Outstanding at beginning of year		10,134,829		$	8.20
Granted		2,363,575			13.61
Exercised		(828,787	)		0.24
Forfeited and cancelled		(133,364	)		17.19

Outstanding as of September 30, 2016		11,536,253			9.78

Exercisable options		5,887,411			5.05

Vested and expected to vest		11,329,415		$	9.71

In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. As of September 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares had been issued under the ESPP.

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

	Nine months ended September 30,					Year ended December 31,
	2016			2015		2015
	Unaudited					Audited
Stock Option Plans
Expected term (years)	6.25				6.25	6.25
Expected volatility	59.12%-61.65%			62.50% - 65.80%		59.00%-65.80%
Risk-free interest rate	1.23%-1.88%			1.75% - 1.90%		1.74%-2.05%
Dividend yield	0%			0%		0%
ESPP
Expected term (years)	0.42			-		-
Expected volatility		70.45	%	-		-
Risk-free interest rate		0.40	%	-		-
Dividend yield	0%			-		-

- 9 -

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:

	Three months ended September 30,				Nine months ended September 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
Cost of revenues	$	160	$	35	$	471	$	54	$	174
Research, development and clinical trials		776		668		2,378		1,717		2,529
Sales and marketing		1,249		571		3,888		1,550		2,496
General and administrative		3,441		1,654		9,982		4,051		6,661
Total share-based compensation expense	$	5,626	$	2,928	$	16,719	$	7,372	$	11,860

NOTE 7: SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:

	September 30,		December 31,
	2016		2015
	Unaudited		Audited
United States	$	11,792	$	6,600
Switzerland		3,769		4,204
Israel		1,934		1,376
Others		433		401
Total	$	17,928	$	12,581

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,				Year ended December 31,
	2016		2015		2016		2015		2015
	Unaudited				Unaudited				Audited
United States	$	18,131	$	8,546	$	46,264	$	19,710	$	30,961
EMEA		3,519		407		6,296		994		2,070
Japan		24		-		86		-		56
Total	$	21,674	$	8,953	$	52,646	$	20,704	$	33,087

NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS

In January 2015, the Company entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. As of September 30, 2016, there is $100,000 outstanding under the Term Loan Credit Facility.

Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year anniversaries, respectively, from the initial funding date. The entire outstanding principal loan is due in January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of September 30, 2016, the Company was in compliance with such covenants.

- 10 -

The total discount of $2,019 and additional issuance costs of $2,744 are presented net of the loan and are amortized to interest expense over the term of the loan using the effective interest method.

NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT

The Company received U.S. Food and Drug Administration approval on its Premarket Approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016. Manufacturing of the first generation Optune System has been terminated. For the nine months ended September 30, 2016, the Company recorded an impairment loss in the second quarter with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.

- 11 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide information to assist you in better understanding and evaluating our financial condition and results of operations. We encourage you to read this MD&A in conjunction with our consolidated financial statements for the period ended September 30, 2016 included in Part I, Item 1 of this Quarterly Report on Form 10-Q. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under Part I, Item 1A, “Risk Factors”, of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”), our actual results may differ materially from those anticipated in these forward-looking statements. References to the words “we,” “our,” “us,” and the “Company” in this report refer to NovoCure Limited, including its consolidated subsidiaries.

Overview

We are a commercial-stage oncology company developing a novel, proprietary therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on key molecules inside cancer cells, disrupting the basic machinery necessary for normal cell division, leading to cancer cell death. Physicians have typically treated patients with solid tumors using one or a combination of three principal treatment modalities—surgery, radiation and pharmacological therapies. Despite meaningful advancements in each of these modalities, a significant unmet need to improve survival and quality of life remains. We believe we will establish TTFields as a new treatment modality for a variety of solid tumors that increases survival without significantly increasing side effects when used in combination with other cancer treatment modalities.

We were founded in 2000 and operated as a development stage company through December 31, 2011. We initially received U.S. Food and Drug Administration (“FDA”) approval for Optune®, our first commercial TTFields delivery system, in 2011 for use as a monotherapy treatment for adult patients with glioblastoma brain cancer (“GBM”) following confirmed recurrence following chemotherapy, after surgical and radiation options have been exhausted. In November 2014, our phase 3 pivotal trial of Optune in combination with chemotherapy for patients with newly diagnosed GBM met its endpoints after a pre-specified interim analysis showed significant improvements in both progression free and overall survival.

In October 2015, we received FDA approval to market Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide (“TMZ”), a chemotherapy drug, following maximum debulking surgery and completion of radiation therapy. In July 2016, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology® (NCCN Guidelines®) for Central Nervous Systems Cancers were updated and now include alternating electric fields therapy (Optune) in combination with TMZ following standard brain radiation therapy with concurrent TMZ as a Category 2A recommended postoperative adjuvant treatment option for patients with newly diagnosed supratentorial GBM.

In September 2016, we announced that the long-term analysis of the full 695 patient dataset from the phase 3 pivotal trial of Optune in combination with TMZ for patients with newly diagnosed GBM was confirmatory of the interim analysis results. The long-term analysis shows survival rates were significantly higher two, three and four years from randomization in patients receiving Optune with TMZ compared to patients receiving TMZ alone. The long-term analysis will be presented as a late-breaking oral presentation at the 21^st Annual Scientific Meeting of the Society of Neuro-Oncology in November 2016.

We have built a commercial organization and launched Optune in the United States, Germany, Switzerland and Japan, which we refer to as our currently active markets. As we enter each new market, our commercial activities focus initially on establishing the required in-market infrastructure, certifying physicians to prescribe Optune and obtaining a defined reimbursement pathway. Once established, our commercial efforts turn to increasing adoption.

We continued to work with payers in the United States to expand access to Optune for patients with newly diagnosed and recurrent GBM in the third quarter of 2016. Payers administering plans for 130 million lives in aggregate have now issued positive coverage policies stating that Optune is approved for the treatment of newly diagnosed or recurrent glioblastoma, an increase of 14 million from the prior quarter. Additionally, we have negotiated contracts, which we anticipate will become effective during the fourth quarter of 2016, to establish Optune as an in-network benefit for more than 120 million lives.

The percentage of our U.S. active patient population who are beneficiaries of the Medicare fee-for-service program continues to range from 20 to 25 percent. We have not received material payments from that program and these invoices remain open as we appeal the coverage denials through the heavily backlogged administrative law judge-controlled proceeding.

We continue to invest in the improvement of Optune to enhance ease of use for patients. A second generation Optune System that is less than half the weight and size of the first generation Optune System was launched in Europe in the fourth quarter of 2015. We

- 12 -

received FDA approval on the premarket approval supplement application to market the second generation Optune System in the United States in July 2016 and have since made the second generation Optune System available to all U.S. patients. Manufacturing of the first generation Optune System has been terminated.

In December 2015, we submitted a partial amendment application to the Japanese Pharmaceuticals and Medical Devices Agency (“PMDA”) in connection with our application for approval of Optune for the treatment of patients with newly diagnosed GBM. We hope to receive Japanese Ministry of Health, Labour and Welfare (“MHLW”) approval for this indication in late 2016. In July 2016, we submitted a partial amendment application to the PMDA in connection with our application for approval of the second generation Optune System. The MHLW approved the use of Optune to treat patients with recurrent GBM in March 2015. We plan to wait until we receive MHLW approval for the use of Optune to treat patients with newly diagnosed GBM before we submit an application for public reimbursement of Optune in Japan.

We have researched the biological effects of TTFields extensively. Because TTFields are delivered regionally, act only on mitotic cells and are tuned to target cells of a specific size, there is minimal damage to healthy cells. We believe our pre-clinical and clinical research demonstrates that TTFields’ mechanism of action affects fundamental aspects of cell division and can have broad applicability across a variety of solid tumors. We have demonstrated in pre-clinical studies that TTFields can offer additive or synergistic benefits in combination with radiation, certain chemotherapy, and certain immunotherapy, which may lead to greater efficacy than radiation, chemotherapy, and immunotherapy alone, without appearing to increase the side effects of the other cancer treatments. In addition to our clinical and commercial progress in GBM, we are currently planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (“NSCLC”), pancreatic cancer, ovarian cancer and mesothelioma.

Results from the first cohort of our PANOVA trial, a phase 2 pilot trial in advanced pancreatic adenocarcinoma examining TTFields in combination with chemotherapy, were presented at the American Society of Clinical Oncology (“ASCO”) Gastrointestinal Cancers Symposium in January 2016, with additional subgroup analyses presented at the ASCO Annual Meeting in June 2016. The first cohort was designed to test the feasibility, safety and preliminary efficacy of TTFields in combination with gemcitabine, a chemotherapy drug, and included 20 patients with advanced pancreatic cancer whose tumors could not be removed surgically and who had not received chemotherapy or radiation therapy prior to the clinical trial. Efficacy results based on the 20 patients in the first cohort showed that progression-free survival (“PFS”) and overall survival (“OS”) of patients treated with TTFields combined with gemcitabine were more than double those of gemcitabine-treated historical controls. Of the 20 patients in the first cohort of the trial, 13 had distant metastases and seven had locally advanced unresectable disease. The median OS for all patients was 14.9 months. Median OS was longer than 15 months in locally advanced patients with 86% of patients alive at end of follow up. Patients with metastatic disease experienced a median OS of 8.3 months. The one-year survival rate was 55%; 86% in patients with locally advanced unresectable disease and 40% in patients with metastatic disease. Adverse events reported in this combination study were comparable to those reported with gemcitabine alone, suggesting minimal added toxicities due to TTFields.

Following the approval of nab-paclitaxel, a taxane-based chemotherapy, for the treatment of advanced pancreatic cancer, the PANOVA study was expanded to include 20 additional patients treated with TTFields in combination with nab-paclitaxel and gemcitabine. We finished enrollment of the second patient cohort in May 2016. With an expected six month follow-up period, we anticipate that phase 2 pilot data will be available in December 2016.

We also finished enrollment in our INNOVATE trial, a phase 2 pilot trial in recurrent ovarian cancer examining TTFields in combination with weekly paclitaxel, in May 2016. With an expected six month follow-up period, we anticipate that phase 2 pilot data will be available in December 2016.

In May 2016, we received FDA approval of our Investigational Device Exemption (“IDE”) application to initiate the METIS trial, a phase 3 pivotal trial studying radiosurgery plus TTFields compared to radiosurgery alone for brain metastases from non-small cell lung cancer. We enrolled the first patient in the trial in October 2016 and anticipate enrolling the last patient in 2019. Given the recent advances in our METIS trial, we closed enrollment for COMET, our phase 2 pilot trial in brain metastases, in July 2016.

In addition, we have developed the protocol for our LUNAR trial, a phase 3 pivotal trial studying TTFields in combination with PD-1 inhibitors or docetaxel for second line treatment of non-small cell lung cancer. We are in discussions with the FDA leading up to the submission of our IDE application and we hope to receive FDA approval of our IDE application in 2017.

- 13 -

The table below presents the current status of our clinical pipeline. We anticipate expanding our clinical pipeline over time to study the safety and efficacy of TTFields for additional solid tumor indications.

We own all commercialization rights to TTFields in oncology. Our robust global patent and intellectual property portfolio consists of over 50 issued patents, with numerous additional patent applications pending worldwide. We believe we will maintain exclusive rights to market TTFields for all solid tumor indications in our key markets through the life of our patents.

Financial Overview. We expect to continue to incur significant expenses and operating losses for at least the next several years. We expect our research, development and clinical trials expenses to increase in connection with our ongoing activities, and as additional indications enter late-stage clinical development. In addition, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We may need additional funding to support the continuation of our operating activities. Until we can generate substantial revenues (which may not occur), we expect to finance our cash needs through our existing cash, cash equivalents, and short-term investments, equity issuances or additional debt, and possibly also from collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We will need to generate significant revenues to achieve profitability, and we may never do so.

Critical accounting policies and estimates

In accordance with U.S. GAAP, in preparing our financial statements, we must make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. We develop and periodically change these estimates and assumptions based on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.

The critical accounting policies requiring estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements can be found in our 2015 10-K. There have been no material changes to our critical accounting policies and estimates as compared to the critical accounting policies and estimates described in our 2015 10-K.

Results of Operations

We account for revenue when cash is collected and all other revenue recognition criteria have been met. We report certain operating statistics to provide additional insight into the commercial performance of Optune in our currently active markets.

Prescriptions are a leading indicator of Optune demand. The conversion of prescriptions to new patients is driven by the prescription fill rate and the time to fill. The prescription fill rate for the twelve months ended September 30, 2016 was 74%. The increase or decrease in active patients in any given period reflects the number of new patients starting on therapy, driven by filled prescriptions, as compared to the number of patients discontinuing therapy, which reflects the treatment duration for patients starting in prior periods.

- 14 -

The following table includes certain commercial operating statistics for and as of the end of the periods presented.

	Three months ended September 30,				Nine months ended September 30,
Operating statistics	2016		2015		2016		2015
Prescriptions received in period (1)
United States		569		307		1,800		1,108
Germany, Switzerland and other EMEA markets (2) (3)		120		47		301		111
Japan (2)		1		1		1		1
		690		355		2,102		1,220
Active patients at period end (4)
United States		783		408		783		408
Germany, Switzerland and other EMEA markets (2) (3)		202		60		202		60
Japan (2)		-		1		-		1
		985		469		985		469

(1)

A “prescription received” is a commercial order for Optune that is received from a physician certified to treat patients with TTFields therapy for a patient not previously on TTFields therapy. Orders to renew or extend treatment are not included in this total. In the future, we may have regulatory approvals and commercial programs for multiple clinical indications, at which time we will recognize a commercial order as a prescription for the same patient for each clinical indication treated. For example, in the future, a patient may have a prescription for the treatment of lung cancer and a prescription for the treatment of brain metastases from the lung cancer.

(2)	As we enter each new market, our commercial activities focus initially on establishing the required in-market infrastructure, certifying physicians to prescribe Optune and obtaining a defined reimbursement pathway. Once established, our commercial efforts turn to increasing adoption.

(3)	EMEA refers to Europe, the Middle East and Africa.

(4)	An “active patient” is a patient who is on TTFields therapy under a commercial prescription order as of the measurement date, including patients who may be on a temporary break from treatment and who plan to resume treatment in less than 60 days.

We view our operations and manage our business in one operating segment. For the three and nine months ended September 30, 2016, our net revenues were $21.7 million and $52.6 million, respectively, and our net losses were $33.6 million and $109.7 million (including an impairment loss with respect to the write-off of first generation Optune System field equipment in the amount of $6.4 million that is not recoverable and is presented in cost of revenues for the nine months ended September 30, 2016), respectively. Our net loss for the three and nine months ended September 30, 2016 includes $5.6 million and $16.7 million, respectively, in non-cash share-based compensation expense. As of September 30, 2016, we had an accumulated deficit of $497.8 million.

Three months ended September 30, 2016 compared to three months ended September 30, 2015

	Three Months Ended September 30,
	2016		2015		Change		% Change
Net revenues	$	21,674	$	8,953	$	12,721		142	%

Net revenues. Substantially all of our revenues are derived from patients using our TTFields delivery system, marketed as Optune in our currently active markets. We charge patients or their third-party healthcare payers directly on a monthly basis and bear the financial risk of securing payment in the United States and Europe.

We account for revenue when cash is collected and other revenue recognition criteria have been met as we have not yet built up sufficient history with each individual third-party payer to reliably estimate their individual payment patterns. As a result, revenue in the reported periods is a mixture of amounts collected from patients using Optune in the period and amounts collected for use of Optune in prior periods.

Net revenues increased by $12.7 million, or 142%, to $21.7 million for the three months ended September 30, 2016 from $9.0 million for the three months ended September 30, 2015. The increase was primarily due to an increase of $9.6 million in commercial sales of Optune in the United States, driven by an increase in Optune adoption, as well as to an increase of $3.1 million in commercial sales of Optune in our other currently active markets, also driven by an increase in Optune adoption.

- 15 -

Cost of revenues. Our cost of revenues is comprised primarily of (i) cost of the disposable transducer arrays purchased from third-party manufacturers, (ii) depreciation expense for field equipment, including the electric field generator used by patients and (iii) personnel, warranty and overhead costs such as facilities, freight and depreciation of property, plant and equipment associated with managing our inventory, warehousing and order fulfillment functions. Our cost of revenues increased by $5.4 million, or 96%, to $11.1 million for the three months ended September 30, 2016 from $5.7 million for the three months ended September 30, 2015. The change was primarily due to an increase in Optune adoption which caused a $3.1 million increase in the cost of transducer array shipments and a $0.5 million increase in field equipment depreciation expenses. In addition, there was a $1.7 million increase in personnel costs to establish the infrastructure necessary to support an increasing volume of shipments.

Operating Expenses. Our operating expenses consist of research, development and clinical trials, sales and marketing and general and administrative expenses. Personnel costs are a significant component for each category of operating expenses and consist of wages, benefits and bonuses. Personnel costs also include share-based compensation.

	Three Months Ended September 30,
	2016		2015		Change		% Change
Research, development and clinical trials	$	10,233	$	10,211	$	22		0	%
Sales and marketing		15,865		8,916		6,949		78	%
General and administrative		12,723		8,405		4,318		51	%
Total operating expenses	$	38,821	$	27,532	$	11,289
Non-cash expenses:
Share-based compensation expense	$	5,466	$	2,893	$	2,573		89	%
Other non-cash expenses		708		427		281		66	%
Total non-cash expenses	$	6,174	$	3,320	$	2,854		86	%

Total operating expenses, net of non-cash expenses	$	32,647	$	24,212	$	8,435		35	%

Research, development and clinical trials expenses. For the three months ended September 30, 2016 as compared to the same period in 2015, research, development and clinical trials expenses remained consistent at $10.2 million. This was primarily due to a decrease of $0.9 million in clinical trial expenses resulting from the conclusion of our EF-14 phase 3 pivotal trial in newly diagnosed GBM and other GBM trial activities, as well as a reduction in expenses related to the development of our second generation Optune System, offset by an increase of $1.0 million in personnel costs (including an increase of $0.1 million in share-based compensation) and clinical trial expenses related to the start-up of our METIS phase 3 pivotal trial in brain metastases.

Sales and marketing expenses. Sales and marketing expenses increased by $7.0 million, or 78%, to $15.9 million for the three months ended September 30, 2016 from $8.9 million for the three months ended September 30, 2015. The change was primarily due to an increase of $4.3 million in personnel costs (including an increase of $0.7 million in share-based compensation) and an increase of $1.9 million in marketing expenses, reflecting our expanding commercial operations in the United States and Germany and our ongoing efforts to establish commercial operations in Switzerland and Japan.

General and administrative expenses. General and administrative expenses increased by $4.3 million, or 51%, to $12.7 million for the three months ended September 30, 2016 from $8.4 million for the three months ended September 30, 2015. The change was primarily due to an increase of $3.7 million in personnel costs (including an increase of $1.8 million in share-based compensation) and $0.6 million in professional services to support our enterprise resource planning system implementation and public company-related activities.

Financial expenses, net. Financial expenses, net primarily consists of interest expense and related amortization of debt issuance costs under our Loan and Security Agreement dated as of January 7, 2015, between us, as borrower, and Biopharma Secured Investments III Holdings Cayman LP, as lender (the “Term Loan Credit Facility”), interest income from cash balances and short-term investments and gains (losses) from foreign currency transactions. The increase primarily results from interest expenses related to our July 2016 draw of the remaining $75 million of funds available under the Term Loan Credit Facility.

	Three Months Ended September 30,
	2016		2015		Change		% Change
Income tax expenses	$	3,174	$	976	$	2,198		225	%

- 16 -

Income taxes. Income taxes increased by $2.2 million to $3.2 million for the three months ended September 30, 2016 compared to the same period of 2015. The change was primarily attributable to an increase in the statutory tax provisions for Switzerland and the United States, resulting from an increase in commercial activities, as well as an increase in our provision for uncertain tax positions.

Nine months ended September 30, 2016 compared to nine months ended September 30, 2015

Nine months ended September 30,

2016

2015

Change

% Change

Net revenues

52,646

20,704

31,942

154

Net revenues increased by $31.9 million, or 154%, to $52.6 million for the nine months ended September 30, 2016 from $20.7 million for the nine months ended September 30, 2015. The increase was primarily due to an increase of $26.6 million in commercial sales of Optune in the United States, driven by an increase in Optune adoption as well as to an increase of $5.3 million in commercial sales of Optune in our other currently active markets, also driven by an increase in Optune adoption.

Cost of revenues. Our cost of revenues is comprised primarily of (i) cost of the disposable transducer arrays purchased from third-party manufacturers, (ii) depreciation expense for field equipment, including the electric field generator used by patients and (iii) personnel, warranty and overhead costs such as facilities, freight and depreciation of property, plant and equipment associated with managing our inventory, warehousing and order fulfillment functions. Our cost of revenues (excluding the impairment of field equipment described below) increased by $14.6 million, or 102%, to $28.9 million for the nine months ended September 30, 2016 from $14.3 million for the nine months ended September 30, 2015. The change was primarily due to an increase in Optune adoption, which caused an $8.1 million increase in the cost of transducer array shipments and a $1.2 million increase in field equipment depreciation expenses. In addition, there was a $4.7 million increase in personnel costs to establish the infrastructure necessary to support an increasing volume of commercial patients.

We received FDA approval on our PMA supplement application to market our second generation Optune System in the United States in July 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016. Manufacturing of the first generation Optune System has been terminated. In the second quarter, we recorded an impairment loss with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6.4 million that is not recoverable and is presented in cost of revenues. We do not expect the conversion to result in an additional material impairment charge in the future.

	Nine Months Ended September 30,
	2016		2015		Change		% Change
Research, development and clinical trials	$	32,996	$	32,903	$	93		0	%
Sales and marketing		43,771		24,137		19,634		81	%
General and administrative		38,010		22,748		15,262		67	%
Total operating expenses	$	114,777	$	79,788	$	34,989
Non-cash expenses:
Share-based compensation expense	$	16,248	$	7,318	$	8,930		122	%
Other non-cash expenses		2,023		794		1,229		155	%
Total non-cash expenses	$	18,271	$	8,112	$	10,159		125	%

Total operating expenses, net of non-cash expenses	$	96,506	$	71,676	$	24,830		35	%

- 17 -

Research, development and clinical trials expenses. Research, development and clinical trials expenses for the three months ended September 30, 2016 were $33.0 million, an increase of $0.1 million versus the same period in 2015. This was primarily due to a $3.6 million increase in personnel costs (including an increase of $0.7 million in share-based compensation) and clinical trial expenses related to the start-up of our METIS phase 3 pivotal trial in brain metastases, offset by a decrease of $3.5 million in clinical trial expenses resulting from the conclusion of our EF-14 pivotal trial in newly diagnosed GBM and a reduction in expenses related to the development of our second generation Optune System.

Sales and marketing expenses. Sales and marketing expenses increased by $19.7 million, or 81%, to $43.8 million for the nine months ended September 30, 2016 from $24.1 million for the nine months ended September 30, 2015. The change was primarily due to an increase of $11.6 million in personnel costs (including an increase of $2.3 million in share-based compensation) and an increase of $5.5 million in marketing expenses, reflecting our expanding commercial operations in the United States and Germany and our ongoing efforts to establish commercial operations in Switzerland and Japan.

General and administrative expenses. General and administrative expenses increased by $15.3 million, or 67%, to $38.0 million for the nine months ended September 30, 2016 from $22.7 million for the nine months ended September 30, 2015. The change was primarily due to an increase of $10.8 million in personnel costs (including an increase of $6.0 million in share-based compensation), and an increase of $3.3 million in professional services to support our enterprise resource planning system implementation and public company-related activities.

Financial expenses, net. Financial expenses, net primarily consists of interest expense and related debt issuance costs under our Term Loan Credit Facility, interest income from cash balances and short-term investments and gains (losses) from foreign currency transactions.

	Nine Months Ended September 30,
	2016		2015		Change		% Change
Income tax expenses	$	8,944	$	2,986	$	5,958		200	%

Income taxes. Income taxes increased by $5.9 million to $8.9 million for the nine months ended September 30, 2016. The change was primarily attributable to an increase in the statutory tax provisions for Switzerland and the United States resulting from an increase in our commercial activities as well as an increase in our provision for uncertain tax positions.

Liquidity and Capital Resources

Sources of Liquidity

Since inception, we have financed our operations primarily through the issuance and sale of equity and the proceeds from long-term loans. As of September 30, 2016, we had received a total of $711.2 million from these activities. As of September 30, 2016, we had an accumulated deficit of $497.8 million since inception.

Our net losses were $109.7 million for the nine months ended September 30, 2016 and $111.6 million for the year ended December 31, 2015. Our net losses primarily resulted from costs incurred in connection with our pre-clinical and clinical trial programs, costs incurred in our commercial launch efforts, and general and administrative costs necessary to operate as a multi-national oncology business.

As of September 30, 2016, we had $115.8 million of cash and cash equivalents and $119.7 million of short-term investments. We believe our cash and cash equivalents and short term investments as of September 30, 2016, are sufficient for our operations for at least the next 12 months based on our existing business plan and our ability to control the timing of significant expense commitments. We expect that our research, development and clinical trials expenses, sales and marketing expenses and general and administrative expenses will continue to increase over the next several years. As a result, we may need to raise additional capital in the future to fund our operations.

- 18 -

	Nine Months Ended September 30,
	2016			2015
	(in thousands)
Net cash used in operating activities	$	(93,867	)	$	(73,763	)
Net cash provided by investing activities		16,406			10,743
Net cash provided by financing activities		73,796			115,731
Net increase (decrease) in cash and cash equivalents		(3,665	)		52,711
Effect of exchange rates on cash and cash equivalents		64			-
Changes in short-term investments		(30,277	)		(18,000	)
Net increase (decrease) in cash, cash equivalents and short-term investments	$	(33,878	)	$	34,711

Operating activities

Net cash used in operating activities primarily represents our net loss for the periods presented. Adjustments to net loss for non-cash items include depreciation and amortization, share-based compensation, accrued interest and impairments. Operating cash flows are also impacted by changes in operating assets and liabilities, principally inventories, prepaid expenses, trade payables and accrued expenses.

Net cash used in operating activities was $93.9 million for the nine months ended September 30, 2016, as compared to $73.8 million for the nine months ended September 30, 2015, reflecting a net loss of $109.7 million and a change of $11.7 million in our net operating assets and liabilities, partially offset by non-cash charges of $27.5 million, which includes $6.4 million of field equipment impairment.

The change in our net operating assets and liabilities was primarily the result of an increase in our inventories of $10.4 million necessary to meet anticipated demand, a decrease in trade payables of $2.6 million offset by an increase in other payables of $2.4 million and other receivables of $1.5 million. Non-cash charges included $16.7 million of share-based compensation, $6.4 million of field equipment impairment and $4.0 million of depreciation.

Investing activities

Our investing activities consist primarily of capital expenditures to purchase property and equipment and field equipment, as well as investments in and redemptions of our short-term investments.

Net cash provided by investing activities was $16.4 million in the nine months ended September 30, 2016 attributable to our receipt of $270.0 million from the maturity of short-term investments, partially offset by the purchase of $239.3 million of new short-term investments, purchases of $5.0 million of property and equipment and purchases of $9.2 million of field equipment. Net cash used in investing activities for the same period in 2015 was $10.7 million, attributable to the receipt of $77.0 million from the maturity of short-term investments, offset by the purchase of $59.0 million of short-term investments, purchases of $3.6 million of property and equipment and purchases of $3.5 million of field equipment.

Financing activities

To date, our primary financing activities have been the sale of equity and the proceeds from long-term loans.

Net cash provided by financing activities consist primarily of approximately $72.9 million net proceeds from our Term Loan Credit Facility and $0.9 million received from the exercise of warrants and options by investors and employees during the nine months ended September 30, 2016. Net cash provided by financing activities was $115.7 million in the same period of 2015, attributable to a draw under our Term Loan Credit Facility and consideration received from the sale of Series J preferred shares in the second quarter of 2015.

Our material outstanding indebtedness consists of our Term Loan Credit Facility. As of September 30, 2016, the aggregate principal balance of amounts outstanding under the Term Loan Credit Facility was $100.0 million. We may prepay the term loans, in whole, at any time, and must prepay in the event of a change of control, in each case, subject to a pay-down fee, prepayment premium and/or make-whole payment. Interest on the outstanding loan is 10% annually, payable quarterly in arrears. The funding fee payable on the amount drawn on the funding date is 1.5%, the placement fee payable on the amount drawn on the funding date is 1.25%, the pay-down fee on all principal payments to be paid on the date such payments are made is 0.75% and the pre-payment fee if we prepay outstanding loan amounts prior to the first, second or third year from the initial funding date is 3.0%, 2.0% or 1.0%, respectively.

- 19 -

All obligations under the Term Loan Credit Facility are guaranteed by certain of our current and future domestic direct and indirect subsidiaries. In addition, the obligations under the Term Loan Credit Facility are secured by a first-priority security interest in substantially all of the property and assets of, as well as the equity interests owned by, us and the other guarantors.

The Term Loan Credit Facility has a minimum liquidity covenant, which is tested quarterly. In addition, we must meet certain pro forma net sales requirements. The Term Loan Credit Facility also contains other customary covenants.

Contractual Obligations and Commitments

There were no material changes in our commitments under contractual obligations during the three months ended September 30, 2016.

The total amount of unrecognized tax benefits for uncertain tax positions was $2.5 million and $1.6 million at September 30, 2016 and December 31, 2015, respectively. Payment of these obligations would result from settlements with taxing authorities. We do not expect a significant tax payment related to these obligations within the next year.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules.

JOBS Act Election

The Jumpstart our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have irrevocably elected to “opt out” of the exemption for the delayed adoption of certain accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2016, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2016, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended September 30, 2016, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

- 20 -

PART II—OTHER INFORMATION

Item 6. Exhibits

EXHIBIT INDEX

Exhibit		Incorporated by Reference			Filed
Number	Exhibit Description	Form	Date	Number	Herewith

10.1	Employment Agreement, dated as of October 10, 2016, by and between NovoCure (Israel) Ltd. and Asaf Danziger	8-K	10/14/16	10.1
10.2	Employment Agreement, dated as of October 10, 2016, by and between Novocure USA LLC and Wilhelmus Groenhuysen	8-K	10/14/16	10.2
10.3	Employment Agreement, dated as of October 10, 2016, by and between Novocure USA LLC and Michael Ambrogi	8-K	10/14/16	10.3
31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended				X
31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended				X
32.1*	Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X
32.2*	Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X
101.INS	XBRL Instance Document				X
101.SCH	XBRL Taxonomy Extension Schema Document				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	XBRL Extension Presentation Linkbase Document				X

The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.

- 21 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		NovoCure Limited

Date: November 2, 2016		/s/ Wilco Groenhuysen
		Wilco Groenhuysen
		Chief Financial Officer
		(principal financial and accounting officer and duly authorized officer)

- 22 -

EXHIBIT INDEX

Exhibit		Incorporated by Reference			Filed
Number	Exhibit Description	Form	Date	Number	Herewith

10.1	Employment Agreement, dated as of October 10, 2016, by and between NovoCure (Israel) Ltd. and Asaf Danziger	8-K	10/14/16	10.1
10.2	Employment Agreement, dated as of October 10, 2016, by and between Novocure USA LLC and Wilhelmus Groenhuysen	8-K	10/14/16	10.2
10.3	Employment Agreement, dated as of October 10, 2016, by and between Novocure USA LLC and Michael Ambrogi	8-K	10/14/16	10.3
31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended				X
31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended				X
32.1*	Certification of Principal Executive Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X
32.2*	Certification of Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350				X
101.INS	XBRL Instance Document				X
101.SCH	XBRL Taxonomy Extension Schema Document				X
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document				X
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document				X
101.LAB	XBRL Taxonomy Extension Label Linkbase Document				X
101.PRE	XBRL Extension Presentation Linkbase Document				X

- 23 -

EX-31.1 2 nvcr-ex311_15.htm EX-31.1 nvcr-ex311_15.htm

Exhibit 31.1

CERTIFICATIONS

I, Asaf Danziger, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NovoCure Limited;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: November 2, 2016

/s/ Asaf Danziger

Asaf Danziger

Chief Executive Officer and Director

(Principal Executive Officer)

EX-31.2 3 nvcr-ex312_14.htm EX-31.2 nvcr-ex312_14.htm

Exhibit 31.2

CERTIFICATIONS

I, Wilco Groenhuysen, certify that:

I have reviewed this Quarterly Report on Form 10-Q of NovoCure Limited;

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

Date: November 2, 2016

/s/ Wilco Groenhuysen

Wilco Groenhuysen

Chief Financial Officer

(Principal Accounting and Financial Officer)

EX-32.1 4 nvcr-ex321_13.htm EX-32.1 nvcr-ex321_13.htm

Exhibit 32.1

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Asaf Danziger, Chief Executive Officer (Principal Executive Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Asaf Danziger

Asaf Danziger

Chief Executive Officer

(Principal Executive Officer)

Date: November 2, 2016

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff on request.

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NovoCure Limited under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 nvcr-ex322_16.htm EX-32.2 nvcr-ex322_16.htm

Exhibit 32.2

NOVOCURE LIMITED

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of NovoCure Limited (the "Company") on Form 10-Q for the quarter ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Wilco Groenhuysen, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Wilco Groenhuysen

Wilco Groenhuysen

Chief Financial Officer

(Principal Financial and Accounting Officer)

Date: November 2, 2016

GRAPHIC 6 g201611012127470148601.jpg GRAPHIC begin 644 g201611012127470148601.jpg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end EX-101.INS 7 nvcr-20160930.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure 0001645113 2016-01-01 2016-09-30 0001645113 2016-10-27 0001645113 2016-09-30 0001645113 2015-12-31 0001645113 2015-01-01 2015-12-31 0001645113 2016-07-01 2016-09-30 0001645113 2015-07-01 2015-09-30 0001645113 2015-01-01 2015-09-30 0001645113 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001645113 us-gaap:RetainedEarningsMember 2014-12-31 0001645113 2014-12-31 0001645113 us-gaap:CommonStockMember 2014-12-31 0001645113 us-gaap:PreferredStockMember 2014-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-12-31 0001645113 us-gaap:CommonStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember nvcr:SeriesJPreferredStockMember 2015-01-01 2015-12-31 0001645113 nvcr:SeriesJPreferredStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:PreferredStockMember nvcr:SeriesJPreferredStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember us-gaap:OverAllotmentOptionMember 2015-01-01 2015-12-31 0001645113 us-gaap:OverAllotmentOptionMember 2015-01-01 2015-12-31 0001645113 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2015-01-01 2015-12-31 0001645113 us-gaap:PreferredStockMember 2015-01-01 2015-12-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-01-01 2015-12-31 0001645113 us-gaap:RetainedEarningsMember 2015-01-01 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001645113 us-gaap:RetainedEarningsMember 2015-12-31 0001645113 us-gaap:CommonStockMember 2015-12-31 0001645113 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001645113 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0001645113 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001645113 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001645113 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001645113 us-gaap:RetainedEarningsMember 2016-09-30 0001645113 us-gaap:CommonStockMember 2016-09-30 0001645113 nvcr:SeriesJPreferredStockMember 2016-01-01 2016-09-30 0001645113 us-gaap:OverAllotmentOptionMember 2016-01-01 2016-09-30 0001645113 2016-06-30 0001645113 2015-06-30 0001645113 2015-09-30 0001645113 us-gaap:MaximumMember 2016-01-01 2016-09-30 0001645113 us-gaap:VehiclesMember 2016-01-01 2016-09-30 0001645113 us-gaap:VehiclesMember us-gaap:MaximumMember 2016-01-01 2016-09-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareOneMember 2016-01-01 2016-09-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareOneMember 2016-09-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareTwoMember 2016-01-01 2016-09-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareThreeMember 2016-01-01 2016-09-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareTwoMember 2016-09-30 0001645113 nvcr:WarrantsToPurchaseOrdinaryShareThreeMember 2016-09-30 0001645113 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001645113 nvcr:TwoThousandFifteenPlanMember 2016-01-01 2016-09-30 0001645113 nvcr:TwoThousandFifteenPlanMember 2016-09-30 0001645113 us-gaap:EmployeeStockMember 2016-09-30 0001645113 us-gaap:EmployeeStockMember 2016-01-01 2016-09-30 0001645113 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-09-30 0001645113 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001645113 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-12-31 0001645113 nvcr:CostOfRevenueMember 2016-07-01 2016-09-30 0001645113 nvcr:CostOfRevenueMember 2015-07-01 2015-09-30 0001645113 nvcr:CostOfRevenueMember 2016-01-01 2016-09-30 0001645113 nvcr:CostOfRevenueMember 2015-01-01 2015-09-30 0001645113 nvcr:CostOfRevenueMember 2015-01-01 2015-12-31 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2016-07-01 2016-09-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-09-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001645113 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-12-31 0001645113 nvcr:SalesAndMarketingMember 2016-07-01 2016-09-30 0001645113 nvcr:SalesAndMarketingMember 2015-07-01 2015-09-30 0001645113 nvcr:SalesAndMarketingMember 2016-01-01 2016-09-30 0001645113 nvcr:SalesAndMarketingMember 2015-01-01 2015-09-30 0001645113 nvcr:SalesAndMarketingMember 2015-01-01 2015-12-31 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2016-07-01 2016-09-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-09-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001645113 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-12-31 0001645113 country:US 2016-09-30 0001645113 country:US 2015-12-31 0001645113 country:CH 2016-09-30 0001645113 country:CH 2015-12-31 0001645113 country:IL 2016-09-30 0001645113 country:IL 2015-12-31 0001645113 nvcr:OthersCountriesMember 2016-09-30 0001645113 nvcr:OthersCountriesMember 2015-12-31 0001645113 country:US 2016-07-01 2016-09-30 0001645113 country:US 2015-07-01 2015-09-30 0001645113 country:US 2016-01-01 2016-09-30 0001645113 country:US 2015-01-01 2015-09-30 0001645113 country:US 2015-01-01 2015-12-31 0001645113 us-gaap:EMEAMember 2016-07-01 2016-09-30 0001645113 us-gaap:EMEAMember 2015-07-01 2015-09-30 0001645113 us-gaap:EMEAMember 2016-01-01 2016-09-30 0001645113 us-gaap:EMEAMember 2015-01-01 2015-09-30 0001645113 us-gaap:EMEAMember 2015-01-01 2015-12-31 0001645113 country:JP 2016-07-01 2016-09-30 0001645113 country:JP 2016-01-01 2016-09-30 0001645113 country:JP 2015-01-01 2015-12-31 0001645113 nvcr:TermLoanMember 2015-01-01 2015-01-31 0001645113 nvcr:TermLoanMember 2015-01-31 0001645113 nvcr:TermLoanMember 2016-06-30 0001645113 nvcr:TermLoanMember 2016-01-01 2016-09-30 0001645113 nvcr:TermLoanMember 2016-09-30 0001645113 us-gaap:DebtInstrumentRedemptionPeriodOneMember nvcr:TermLoanMember 2016-01-01 2016-09-30 0001645113 us-gaap:DebtInstrumentRedemptionPeriodTwoMember nvcr:TermLoanMember 2016-01-01 2016-09-30 0001645113 us-gaap:DebtInstrumentRedemptionPeriodThreeMember nvcr:TermLoanMember 2016-01-01 2016-09-30 0001645113 us-gaap:OtherNoncurrentAssetsMember nvcr:TermLoanMember 2016-09-30 0001645113 nvcr:FirstGenerationOptuneSystemFieldEquipmentMember nvcr:CostOfRevenueMember 2016-01-01 2016-09-30 10-Q false 2016-09-30 2016 Q3 NVCR Novocure Ltd 0001645113 --12-31 Non-accelerated Filer 86780413 115822000 119423000 119724000 150001000 72000 87000 11840000 10799000 23972000 13594000 271430000 293904000 9886000 6552000 8042000 6029000 89000 79000 1646000 772000 19663000 13432000 291093000 307336000 15243000 16755000 14469000 11872000 29712000 28627000 95970000 23097000 3132000 2057000 4036000 2735000 103138000 27889000 132850000 56516000 0 0 0 0 658086000 640406000 -2085000 -1505000 -497758000 -388081000 158243000 250820000 291093000 307336000 0 0 Unlimited Unlimited 85775203 83778581 85775203 83778581 21674000 8953000 52646000 20704000 33087000 11118000 5659000 28897000 14306000 20610000 6412000 10556000 3294000 17337000 6398000 12477000 10233000 10211000 32996000 32903000 43748000 15865000 8916000 43771000 24137000 38861000 12723000 8405000 38010000 22748000 33864000 38821000 27532000 114777000 79788000 116473000 -28265000 -24238000 -97440000 -73390000 -103996000 2189000 809000 3293000 2277000 3151000 -30454000 -25047000 -100733000 -75667000 -107147000 3174000 976000 8944000 2986000 4434000 -33628000 -26023000 -109677000 -78653000 -111581000 -0.39 -2.09 -1.29 -6.21 -3.67 85774874 12431586 85153644 12666455 30401603 8000 64000 409000 644000 1505000 -34029000 -26023000 -110257000 -78653000 -113086000 374375000 -276500000 97875000 13431414 58676017 11860000 11860000 2038000 2038000 731665 94599000 94599000 4068500 1005210 157534000 157534000 7876195 62744517 -62744517 -1505000 -1505000 -111581000 640406000 -1505000 -388081000 83778581 16719000 16719000 961000 961000 1996622 -580000 -580000 -109677000 658086000 -2085000 -497758000 85775203 319000 15742000 1553000 893000 4063000 2005000 3153000 10000 6440000 42000 46000 222000 -565000 222000 154000 672000 5626000 2928000 16719000 7372000 11860000 81000 88000 25000 231000 329000 -694000 1427000 1514000 4453000 5088000 2757000 2556000 10378000 7703000 10148000 526000 -250000 804000 -79000 381000 -6765000 1512000 -2621000 4597000 6961000 1651000 2374000 2407000 2892000 3579000 80000 -10000 350000 -3000 133000 263000 430000 901000 -323000 581000 -33496000 -22106000 -93867000 -73763000 -99884000 1715000 1196000 5055000 3613000 4667000 3113000 1367000 9213000 3547000 5604000 -27000 72000 -15000 105000 26000 120000000 30000000 270000000 77000000 104000000 119613000 239341000 58992000 208998000 -4414000 27365000 16406000 10743000 -115295000 94599000 252133000 72870000 72887000 22886000 22886000 1439000 1733000 17000 16000 52000 47000 63000 5000 5000 12000 961000 31000 2038000 72853000 -1443000 73796000 115731000 276989000 8000 64000 34951000 3816000 -3601000 52711000 61810000 80871000 106508000 57613000 110324000 4624000 658000 7793000 1683000 1489000 1880000 1252000 3813000 823000 1688000 <div> NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION Organization.  NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015. Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements. Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting. In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.</div> <div> NOTE 2: SHORT-TERM INVESTMENTS The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,724 and $150,001 as of September 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of September 30, 2016 and December 31, 2015 was $119,604 and $149,978, respectively.</div> <div> NOTE 3: INVENTORIES Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,518</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in progress</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,621</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,618</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished products</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,834</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,972</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,594</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019. As of September 30, 2016 and December 31, 2015, the Company pledged bank deposits of $807 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $962 and $283, respectively.</div> <div> NOTE 5: SHARE CAPITAL For the nine months ended September 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644 and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the nine months ended September 30, 2016, options to purchase 825,240 ordinary shares were exercised for cash and options to purchase 3,547 ordinary shares were cashlessly exercised, resulting in the issuance of 825,669 ordinary shares.  For additional information on option exercises, please see Note 6.</div> <div> NOTE 6: EQUITY INCENTIVE PLAN In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan.  Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.   The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant. As of September 30, 2016, 12,717,460 ordinary shares were available for grant under the 2015 Plan.   A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at beginning of year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,134,829</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,363,575</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(828,787</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,364</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.19</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,536,253</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,887,411</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.05</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,329,415</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.71</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016.  As of September 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares had been issued under the ESPP. The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Option Plans</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.12%-61.65%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.50% - 65.80%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.00%-65.80%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23%-1.88%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75% - 1.90%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.74%-2.05%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ESPP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.42</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> -</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.45</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> </table></div>   The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, development and clinical <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   trials</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,378</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,717</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,529</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,888</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,550</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,496</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,982</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,051</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,719</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> NOTE 7: SUPPLEMENTAL INFORMATION The Company operates in a single reportable segment. The following table presents long-lived assets by location:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,792</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,600</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,769</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,204</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,934</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,376</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,928</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,581</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,131</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,546</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,264</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,710</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,961</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EMEA</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,519</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,296</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,674</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,953</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,646</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,704</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,087</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2015, the Company entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. As of September 30, 2016, there is $100,000 outstanding under the Term Loan Credit Facility. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year anniversaries, respectively, from the initial funding date. The entire outstanding principal loan is due in January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of September 30, 2016, the Company was in compliance with such covenants. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total discount of $2,019 and additional issuance costs of $2,744 are presented net of the loan and are amortized to interest expense over the term of the loan using the effective interest method.</div> <div> NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT   <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received U.S. Food and Drug Administration approval on its Premarket Approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016.  Manufacturing of the first generation Optune System has been terminated. For the nine months ended September 30, 2016, the Company recorded an impairment loss in the second quarter with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.  </div> <div> Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting. In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.</div> <div> Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Raw materials</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,517</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,518</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Work in progress</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,621</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,618</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finished products</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,834</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,458</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,972</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,594</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.44%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at beginning of year</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,134,829</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.20</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,363,575</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.61</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(828,787</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited and cancelled</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(133,364</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.19</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of September 30, 2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,536,253</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.78</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable options</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,887,411</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.05</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,329,415</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.71</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:    <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.7%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Option Plans</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.25</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.12%-61.65%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62.50% - 65.80%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.00%-65.80%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23%-1.88%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75% - 1.90%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.74%-2.05%</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ESPP</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.42</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> -</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70.45</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> <tr> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0%</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.18%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> </tr> </table></div>  </div> <div> The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine months ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research, development and clinical <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   trials</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,378</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,717</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,529</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,249</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,888</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,550</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,496</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,441</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,654</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,982</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,051</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,661</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total share-based compensation <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   expense</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,626</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,928</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,719</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,860</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The following table presents long-lived assets by location:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,792</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,600</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switzerland</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,769</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,204</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.9%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Israel</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,934</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,376</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">401</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.9%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,928</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,581</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> <div> The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unaudited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Audited</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,131</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,546</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,264</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,710</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,961</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.12%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EMEA</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,519</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">407</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,296</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">994</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,070</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.12%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,674</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,953</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,646</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,704</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,087</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div> 119604000 149978000 4517000 3518000 9621000 4618000 9834000 5458000 The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. 2024 The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019. 2019 807000 133000 962000 283000 220316 3.59 220316 975644 888219 18.09 3.59 950637 825240 3547 825669 P4Y P10Y 12717460 10134829 2363575 828787 133364 11536253 5887411 11329415 8.20 13.61 0.24 17.19 9.78 5.05 9.71 1667785 0 P6Y3M P6Y3M P6Y3M 0.5912 0.6250 0.5900 0.6165 0.6580 0.6580 0.0123 0.0175 0.0174 0.0188 0.0190 0.0205 0.00 0.00 0.00 P5M 0.7045 0.0040 0.00 160000 35000 471000 54000 174000 776000 668000 2378000 1717000 2529000 1249000 571000 3888000 1550000 2496000 3441000 1654000 9982000 4051000 6661000 5626000 2928000 16719000 7372000 11860000 11792000 6600000 3769000 4204000 1934000 1376000 433000 401000 17928000 12581000 18131000 8546000 46264000 19710000 30961000 3519000 407000 6296000 994000 2070000 24000 86000 56000 P5Y 100000000 25000000 75000000 2016-07 100000000 0.10 0.015 0.0075 0.030 0.020 0.010 2020-01-31 Quarterly 2019000 2744000 6412000 1582000 Net of issuance expenses of $319 Net of issuance expenses (including underwriter fees) of $15,742 EX-101.SCH 8 nvcr-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - CONDENSED INTERIM CONSOLIDATED CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Organization and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Short-Term Investments link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Commitments and Contingent Liabilities link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Share Capital link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Equity Incentive Plan link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Supplemental Information link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Impairment of Field Equipment link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Organization and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Equity Incentive Plan (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Supplemental Information (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Short-Term Investments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Inventories - Schedule of Inventories (Details) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Commitments and Contingent Liabilities - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Share Capital - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Equity Incentive Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Plan (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Equity Incentive Plan - Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Supplemental Information - Schedule of Long-Lived Assets by Location (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Supplemental Information - Schedule of Revenues by Geographic Region (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Impairment of Field Equipment - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 9 nvcr-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 nvcr-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 nvcr-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document document and entity information. Document Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Receivables and prepaid expenses. Field equipment, net, noncurrent. Severance pay fund noncurrent. Employee related liabilities noncurrent. Statement Of Financial Position [Abstract] ASSETS Assets [Abstract] CURRENT ASSETS: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Held To Maturity Securities Current Restricted cash Restricted Cash And Cash Equivalents At Carrying Value Receivables and prepaid expenses Receivables And Prepaid Expenses Inventories Inventory Net Total current assets Assets Current LONG-TERM ASSETS: Assets Noncurrent [Abstract] Property and equipment, net Property Plant And Equipment Net Field equipment, net Field Equipment Net Noncurrent Severance pay fund Severance Pay Fund Noncurrent Other long-term assets Other Assets Noncurrent Total long-term assets Assets Noncurrent TOTAL ASSETS Assets LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities And Stockholders Equity [Abstract] CURRENT LIABILITIES: Liabilities Current [Abstract] Trade payables Accounts Payable Trade Current Other payables and accrued expenses Other Accounts Payable And Accrued Liabilities Total current liabilities Liabilities Current LONG-TERM LIABILITIES: Liabilities Noncurrent [Abstract] Long-term loan, net of discount and issuance costs Long Term Debt Noncurrent Employee benefit liabilities Employee Related Liabilities Non Current Other long-term liabilities Other Liabilities Noncurrent Total long-term liabilities Liabilities Noncurrent TOTAL LIABILITIES Liabilities COMMITMENTS AND CONTINGENCIES Commitments And Contingencies SHAREHOLDERS' EQUITY: Stockholders Equity [Abstract] Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,775,203 (unaudited) shares and 83,778,581 shares at September 30, 2016 and December 31, 2015, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders' equity Stockholders Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Unlimited Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Net revenues Sales Revenue Net Cost of revenues Cost Of Revenue Impairment of field equipment Production Related Impairments Or Charges Gross profit Gross Profit Operating costs and expenses: Operating Expenses [Abstract] Research, development and clinical trials Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Total operating costs and expenses Operating Expenses Operating loss Operating Income Loss Financial expenses, net Interest And Debt Expense Loss before income tax expense Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense Income Tax Expense Benefit Net loss Net Income Loss Basic and diluted net loss per ordinary share Earnings Per Share Basic And Diluted Weighted average number of ordinary shares used in computing basic and diluted net loss per share Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss Other comprehensive loss, net of tax : Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract] Change in foreign currency translation adjustments Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Pension benefit plan Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax Total comprehensive loss Comprehensive Income Net Of Tax Stock issued during period value exercise of options and warrants. Stock issued during period shares exercise of options and warrants. Issuances of stock and options shares for settlement net of indemnification. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Ordinary Shares Common Stock [Member] Preferred Shares Preferred Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Outstanding nonredeemable series J preferred stock or outstanding series J preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer. Series J Preferred Stock Series J Preferred Stock [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Over-Allotment Over Allotment Option [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in shares) Shares Outstanding Share-based compensation to employees Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Exercise of options and warrants Stock Issued During Period Value Exercise Of Options And Warrants Exercise of options and warrants (in shares) Stock Issued During Period Shares Exercise Of Options And Warrants Issuance of shares, net Stock Issued During Period Value New Issues Issuance of shares, net (in shares) Stock Issued During Period Shares New Issues Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification (in shares) Issuances Of Stock And Options Shares For Settlement Net Of Indemnification Conversion of preferred shares to ordinary shares Stock Issued During Period Shares Conversion Of Convertible Securities Other comprehensive loss, net of tax benefit Other Comprehensive Income Loss Net Of Tax Balance Balance (in shares) Share issuance expenses Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Increase (decrease) in receivables and prepaid expenses. Payments to acquire of field equipment. Cash paid during the period for. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Asset write-downs and impairment of field equipment Asset Impairment Charges Increase (decrease) in accrued interest expense Increase Decrease In Interest Payable Net Share-based compensation to employees Share Based Compensation Amortization of discount Amortization Of Debt Discount Premium Decrease (increase) in receivables and prepaid expenses Increase Decrease In Receivables And Prepaid Expenses Increase in inventories Increase Decrease In Inventories Decrease (increase) in other long-term assets Increase Decrease In Other Noncurrent Assets Increase (decrease) in trade payables Increase Decrease In Accounts Payable Trade Increase in other payables and accrued expenses Increase Decrease In Other Accounts Payable And Accrued Liabilities Increase (decrease) in employee benefit liabilities, net Increase Decrease In Employee Related Liabilities Increase (decrease) in other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Purchase of property and equipment Payments To Acquire Property Plant And Equipment Purchase of field equipment Payments To Acquire Of Field Equipment Decrease (increase) in restricted cash Increase Decrease In Restricted Cash Proceeds from maturity of short-term investments Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities Purchase of short-term investments Payments To Acquire Held To Maturity Securities Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from issuance of shares, net Proceeds From Issuance Of Common Stock Proceeds from long-term loan, net Proceeds From Issuance Of Long Term Debt Deferred IPO costs Payments Of Stock Issuance Costs Repayment of other long-term loan Repayments Of Other Long Term Debt Purchase of shares in respect of settlement Payments For Repurchase Of Common Stock Exercise of options and warrants Proceeds From Issuance Or Sale Of Equity Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Effect of exchange rate changes on cash and cash equivalents Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations Increase (decrease) in cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash paid during the period for: Cash Paid During Period For [Abstract] Income taxes Income Taxes Paid Net Interest Interest Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization and Basis of Presentation Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Marketable Securities Current [Abstract] Short-Term Investments Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingent Liabilities Commitments And Contingencies Disclosure [Text Block] Disclosure of share capital. Share Based Compensation Allocation And Classification In Financial Statements [Abstract] Share Capital Disclosure Of Share Capital [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Equity Incentive Plan Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Geographic Areas Long Lived Assets [Abstract] Supplemental Information Segment Reporting Disclosure [Text Block] Debt Disclosure [Abstract] Long-Term Loan, Net of Discount and Issuance Costs Debt Disclosure [Text Block] Impairment Or Disposal Of Tangible Assets Disclosure [Abstract] Impairment of Field Equipment Restructuring Impairment And Other Activities Disclosure [Text Block] Recently Issued Accounting Pronouncement New Accounting Pronouncements Policy Policy [Text Block] Schedule of Inventories Schedule Of Inventory Current Table [Text Block] Schedule of Stock Option Plans Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model Disclosure Of Share Based Compensation Arrangements By Share Based Payment Award [Text Block] Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Long-Lived Assets by Location Long Lived Assets By Geographic Areas Table [Text Block] Schedule of Revenues by Geographic Region Schedule Of Revenues From External Customers And Long Lived Assets By Geographical Areas Table [Text Block] Investments Debt And Equity Securities [Abstract] Estimated fair value of short-term investments Held To Maturity Securities Fair Value Raw materials Inventory Raw Materials Net Of Reserves Work in progress Inventory Work In Process Net Of Reserves Finished products Inventory Finished Goods Net Of Reserves Total Operating lease expiration description. Operating lease agreement expiration period. Loss Contingencies [Table] Loss Contingencies [Table] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Motor Vehicles Vehicles [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Operating lease expiration description Operating Lease Expiration Description Operating lease agreements, expiration year Operating Lease Agreement Expiration Period Operating lease commitments. Pledged bank deposits Deposits Assets Operating Lease Commitments Operating Lease Commitments Warrants exercised to ordinary shares. Options issued to purchase ordinary shares exercised in cash. Options issued to purchase ordinary shares noncash exercised. Ordinary shares issued upon option exercise. Share capital. Schedule of share capital. Schedule Of Share Capital [Table] Schedule Of Share Capital [Table] Warrants to purchase ordinary share one. Warrants to Purchase 220,316 Ordinary Shares Warrants To Purchase Ordinary Share One [Member] Warrants to purchase ordinary share two. Warrants to Purchase 975,644 Ordinary Shares Warrants To Purchase Ordinary Share Two [Member] Warrants to purchase ordinary share three. Warrants to Purchase 888,219 Ordinary Shares Warrants To Purchase Ordinary Share Three [Member] Warrant Warrant [Member] Share Capital [Line Items] Share Capital [Line Items] Warrants issued to purchase of ordinary shares Debt Conversion Converted Instrument Warrants Or Options Issued1 Warrants exercise price Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants exercised to ordinary shares Warrants Exercised To Ordinary Shares Options issued to purchase ordinary shares exercised for cash Options Issued To Purchase Ordinary Shares Exercised In Cash Options issued to purchase ordinary shares cashlessly exercised Options Issued To Purchase Ordinary Shares Noncash Exercised Ordinary shares issued upon option exercise Ordinary Shares Issued Upon Option Exercise Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand fifteen plan. 2015 Plan Two Thousand Fifteen Plan [Member] ESPP Employee Stock [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Option granted vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Option granted expiration period Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Ordinary shares available for grants Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Number of options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Number of options, Outstanding at beginning of year Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Number of options, Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Number of options, Exercised Stock Issued During Period Shares Stock Options Exercised Number of options, Forfeited and cancelled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Number of options, Outstanding at ending of year Number of options, Exercisable options Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Number of options, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Weighted average exercise price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Weighted average exercise price, Outstanding at beginning of year Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Weighted average exercise price, Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted average exercise price, Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Weighted average exercise price, Forfeited and cancelled Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Weighted average exercise price, Outstanding at end of year Weighted average exercise price, Exercisable options Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Weighted average exercise price, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Shares issued under plan Stock Issued During Period Shares Employee Stock Purchase Plans Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Option Plans Employee Stock Option [Member] Expected term (years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Expected volatility, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum Expected volatility, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum Risk-free interest rate, minimum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum Risk-free interest rate, maximum Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of revenue. Cost of Revenues Cost Of Revenue [Member] Research, Development and Clinical Trials Research And Development Expense [Member] Sales and Marketing. Sales and Marketing Sales And Marketing [Member] General and Administrative General And Administrative Expense [Member] Total share-based compensation expense Allocated Share Based Compensation Expense Schedule Of Revenues From External Customers And Long Lived Assets [Table] Schedule Of Revenues From External Customers And Long Lived Assets [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States UNITED STATES Switzerland SWITZERLAND Israel ISRAEL Others countries. Others Others Countries [Member] Revenues From External Customers And Long Lived Assets [Line Items] Revenues From External Customers And Long Lived Assets [Line Items] Long-lived assets Noncurrent Assets EMEA E M E A [Member] Japan JAPAN Line of credit facility, drawdown received date, Month and Year. Line Of Credit Facility [Table] Line Of Credit Facility [Table] Debt Instrument Debt Instrument [Axis] Debt Instrument, Name Debt Instrument Name [Domain] Term loan. Term Loan Term Loan [Member] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Axis] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Domain] First Year Debt Instrument Redemption Period One [Member] Second Year Debt Instrument Redemption Period Two [Member] Third Year Debt Instrument Redemption Period Three [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Other Long-term Assets Other Noncurrent Assets [Member] Line Of Credit Facility [Line Items] Line Of Credit Facility [Line Items] Term loan agreement, maturity period Debt Instrument Term Line of credit facility, maximum borrowing capacity Line Of Credit Facility Maximum Borrowing Capacity Line of credit facility, current borrowing capacity Line Of Credit Facility Current Borrowing Capacity Line of credit facility, remaining borrowing capacity Line Of Credit Facility Remaining Borrowing Capacity Line of credit facility, drawdown received date Line Of Credit Facility Drawdown Received Date Month And Year Term loan credit facility, outstanding Line Of Credit Facility Maximum Amount Outstanding During Period Funding fees payable. Interest on the outstanding loan Debt Instrument Interest Rate Stated Percentage Funding fees payable Funding Fees Payable Prepayment fee percent Debt Instrument Redemption Price Percentage Due date of outstanding principal loan Debt Instrument Maturity Date Frequency of payments Debt Instrument Frequency Of Periodic Payment Total discount Debt Instrument Unamortized Discount Additional deferred issuance costs Deferred Finance Costs Noncurrent Net Cost of materials purchased and expenses due to vendors. Schedule Of Impaired Long Lived Assets Held And Used [Table] Schedule Of Impaired Long Lived Assets Held And Used [Table] First generation Optune System field equipment. First Generation Optune System Field Equipment First Generation Optune System Field Equipment [Member] Impaired Long Lived Assets Held And Used [Line Items] Impaired Long Lived Assets Held And Used [Line Items] Advances for materials purchased and liabilities incurred to vendors Cost Of Materials Purchased And Expenses Due To Vendors EX-101.PRE 12 nvcr-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2016

Oct. 27, 2016

Document Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2016

Document Fiscal Year Focus 2016

Document Fiscal Period Focus Q3

Trading Symbol NVCR

Entity Registrant Name Novocure Ltd

Entity Central Index Key 0001645113

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Common Stock, Shares Outstanding 86,780,413

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document document and entity information.
+ References
No definition available.
+ Details

Name: nvcr_DocumentDocumentAndEntityInformationAbstract

Namespace Prefix: nvcr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

CURRENT ASSETS:

Cash and cash equivalents $ 115,822 $ 119,423

Short-term investments 119,724 150,001

Restricted cash 72 87

Receivables and prepaid expenses 11,840 10,799

Inventories 23,972 13,594

Total current assets 271,430 293,904

LONG-TERM ASSETS:

Property and equipment, net 9,886 6,552

Field equipment, net 8,042 6,029

Severance pay fund 89 79

Other long-term assets 1,646 772

Total long-term assets 19,663 13,432

TOTAL ASSETS 291,093 307,336

CURRENT LIABILITIES:

Trade payables 15,243 16,755

Other payables and accrued expenses 14,469 11,872

Total current liabilities 29,712 28,627

LONG-TERM LIABILITIES:

Long-term loan, net of discount and issuance costs 95,970 23,097

Employee benefit liabilities 3,132 2,057

Other long-term liabilities 4,036 2,735

Total long-term liabilities 103,138 27,889

TOTAL LIABILITIES 132,850 56,516

COMMITMENTS AND CONTINGENCIES 0 0

SHAREHOLDERS' EQUITY:

Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,775,203 (unaudited) shares and 83,778,581 shares at September 30, 2016 and December 31, 2015, respectively 0 0

Additional paid-in capital 658,086 640,406

Accumulated other comprehensive loss (2,085) (1,505)

Accumulated deficit (497,758) (388,081)

Total shareholders' equity 158,243 250,820

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 291,093 $ 307,336

X

- Definition
Employee related liabilities noncurrent.
+ References
No definition available.
+ Details

Name: nvcr_EmployeeRelatedLiabilitiesNonCurrent

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Field equipment, net, noncurrent.
+ References
No definition available.
+ Details

Name: nvcr_FieldEquipmentNetNoncurrent

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Receivables and prepaid expenses.
+ References
No definition available.
+ Details

Name: nvcr_ReceivablesAndPrepaidExpenses

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Severance pay fund noncurrent.
+ References
No definition available.
+ Details

Name: nvcr_SeverancePayFundNoncurrent

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Liabilities
-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26626-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558
+ Details

Name: us-gaap_HeldToMaturitySecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_OtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
9 Months Ended 12 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Statement Of Financial Position [Abstract]

Common stock, par value $ 0 $ 0

Common stock, shares authorized Unlimited Unlimited

Common stock, shares issued 85,775,203 83,778,581

Common stock, shares outstanding 85,775,203 83,778,581

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorizedUnlimited

Namespace Prefix: us-gaap_

Data Type: us-types:authorizedUnlimitedItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 16 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Income Statement [Abstract]

Net revenues $ 21,674 $ 8,953 $ 52,646 $ 20,704 $ 33,087

Cost of revenues 11,118 5,659 28,897 14,306 20,610

Impairment of field equipment 6,412

Gross profit 10,556 3,294 17,337 6,398 12,477

Operating costs and expenses:

Research, development and clinical trials 10,233 10,211 32,996 32,903 43,748

Sales and marketing 15,865 8,916 43,771 24,137 38,861

General and administrative 12,723 8,405 38,010 22,748 33,864

Total operating costs and expenses 38,821 27,532 114,777 79,788 116,473

Operating loss (28,265) (24,238) (97,440) (73,390) (103,996)

Financial expenses, net 2,189 809 3,293 2,277 3,151

Loss before income tax expense (30,454) (25,047) (100,733) (75,667) (107,147)

Income tax expense 3,174 976 8,944 2,986 4,434

Net loss $ (33,628) $ (26,023) $ (109,677) $ (78,653) $ (111,581)

Basic and diluted net loss per ordinary share $ (0.39) $ (2.09) $ (1.29) $ (6.21) $ (3.67)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share 85,774,874 12,431,586 85,153,644 12,666,455 30,401,603

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Income Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6515339
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest and debt related expenses associated with nonoperating financing activities of the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
+ Details

Name: us-gaap_InterestAndDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_ProductionRelatedImpairmentsOrCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 17 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Statement Of Income And Comprehensive Income [Abstract]

Net loss $ (33,628) $ (26,023) $ (109,677) $ (78,653) $ (111,581)

Other comprehensive loss, net of tax :

Change in foreign currency translation adjustments 8 64

Pension benefit plan (409) (644) (1,505)

Total comprehensive loss $ (34,029) $ (26,023) $ (110,257) $ (78,653) $ (113,086)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b,c)
-URI http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of (increase) decrease in accumulated other comprehensive (income) loss related to pension and other postretirement defined benefit plans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (i-k)
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands

Total

Over-Allotment
^[1]
Series J Preferred Stock
^[2]
Ordinary Shares

Ordinary Shares

Over-Allotment

Preferred Shares

Preferred Shares

Series J Preferred Stock

Additional Paid-in Capital

Additional Paid-in Capital

Over-Allotment
^[1]
Additional Paid-in Capital

Series J Preferred Stock
^[2]
Accumulated Other Comprehensive Loss

Accumulated Deficit

Balance at Dec. 31, 2014 $ 97,875 $ 374,375 $ (276,500)

Balance (in shares) at Dec. 31, 2014 13,431,414 58,676,017

Share-based compensation to employees 11,860 11,860

Exercise of options and warrants 2,038 2,038

Exercise of options and warrants (in shares) 731,665

Issuance of shares, net $ 157,534 $ 94,599 $ 157,534 $ 94,599

Issuance of shares, net (in shares) 7,876,195 4,068,500

Issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification (in shares) (1,005,210)

Conversion of preferred shares to ordinary shares 62,744,517 (62,744,517)

Other comprehensive loss, net of tax benefit (1,505) $ (1,505)

Net loss (111,581) (111,581)

Balance at Dec. 31, 2015 250,820 640,406 (1,505) (388,081)

Balance (in shares) at Dec. 31, 2015 83,778,581

Share-based compensation to employees 16,719 16,719

Exercise of options and warrants 961 961

Exercise of options and warrants (in shares) 1,996,622

Other comprehensive loss, net of tax benefit (580) (580)

Net loss (109,677) (109,677)

Balance at Sep. 30, 2016 $ 158,243 $ 658,086 $ (2,085) $ (497,758)

Balance (in shares) at Sep. 30, 2016 85,775,203

[1] Net of issuance expenses (including underwriter fees) of $15,742

[2] Net of issuance expenses of $319

X

- Definition
Issuances of stock and options shares for settlement net of indemnification.
+ References
No definition available.
+ Details

Name: nvcr_IssuancesOfStockAndOptionsSharesForSettlementNetOfIndemnification

Namespace Prefix: nvcr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock issued during period shares exercise of options and warrants.
+ References
No definition available.
+ Details

Name: nvcr_StockIssuedDuringPeriodSharesExerciseOfOptionsAndWarrants

Namespace Prefix: nvcr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock issued during period value exercise of options and warrants.
+ References
No definition available.
+ Details

Name: nvcr_StockIssuedDuringPeriodValueExerciseOfOptionsAndWarrants

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66904339&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=65896087&loc=d3e11178-113907
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004921&loc=d3e1436-108581
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=nvcr_SeriesJPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical)
$ in Thousands
9 Months Ended

Sep. 30, 2016

USD ($)

Series J Preferred Stock

Share issuance expenses $ 319

Over-Allotment

Share issuance expenses $ 15,742

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=nvcr_SeriesJPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2

CONDENSED INTERIM CONSOLIDATED CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Cash flows from operating activities:

Net loss $ (33,628) $ (26,023) $ (109,677) $ (78,653) $ (111,581)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 1,553 893 4,063 2,005 3,153

Asset write-downs and impairment of field equipment 10 6,440 42 46

Increase (decrease) in accrued interest expense 222 (565) 222 154 672

Share-based compensation to employees 5,626 2,928 16,719 7,372 11,860

Amortization of discount 81 88 25 231 329

Decrease (increase) in receivables and prepaid expenses 694 (1,427) (1,514) (4,453) (5,088)

Increase in inventories (2,757) (2,556) (10,378) (7,703) (10,148)

Decrease (increase) in other long-term assets (526) 250 (804) 79 (381)

Increase (decrease) in trade payables (6,765) 1,512 (2,621) 4,597 6,961

Increase in other payables and accrued expenses 1,651 2,374 2,407 2,892 3,579

Increase (decrease) in employee benefit liabilities, net 80 (10) 350 (3) 133

Increase (decrease) in other long-term liabilities 263 430 901 (323) 581

Net cash used in operating activities (33,496) (22,106) (93,867) (73,763) (99,884)

Cash flows from investing activities:

Purchase of property and equipment (1,715) (1,196) (5,055) (3,613) (4,667)

Purchase of field equipment (3,113) (1,367) (9,213) (3,547) (5,604)

Decrease (increase) in restricted cash 27 (72) 15 (105) (26)

Proceeds from maturity of short-term investments 120,000 30,000 270,000 77,000 104,000

Purchase of short-term investments (119,613) (239,341) (58,992) (208,998)

Net cash provided by (used in) investing activities (4,414) 27,365 16,406 10,743 (115,295)

Cash flows from financing activities:

Proceeds from issuance of shares, net 94,599 252,133

Proceeds from long-term loan, net 72,870 72,887 22,886 22,886

Deferred IPO costs (1,439) (1,733)

Repayment of other long-term loan (17) (16) (52) (47) (63)

Purchase of shares in respect of settlement (5) (5)

Exercise of options and warrants 12 961 31 2,038

Net cash provided by (used in) financing activities 72,853 (1,443) 73,796 115,731 276,989

Effect of exchange rate changes on cash and cash equivalents 8 64

Increase (decrease) in cash and cash equivalents 34,951 3,816 (3,601) 52,711 61,810

Cash and cash equivalents at the beginning of the period 80,871 106,508 119,423 57,613 57,613

Cash and cash equivalents at the end of the period 115,822 110,324 115,822 110,324 119,423

Cash paid during the period for:

Income taxes 4,624 658 7,793 1,683 1,489

Interest $ 1,880 $ 1,252 $ 3,813 $ 823 $ 1,688

X

- Definition
Cash paid during the period for.
+ References
No definition available.
+ Details

Name: nvcr_CashPaidDuringPeriodForAbstract

Namespace Prefix: nvcr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Increase (decrease) in receivables and prepaid expenses.
+ References
No definition available.
+ Details

Name: nvcr_IncreaseDecreaseInReceivablesAndPrepaidExpenses

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Payments to acquire of field equipment.
+ References
No definition available.
+ Details

Name: nvcr_PaymentsToAcquireOfFieldEquipment

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_AssetImpairmentCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent operating liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=51831270

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow for cost incurred directly with the issuance of an equity security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsOfStockIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow through purchase of long-term held-to-maturity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133
+ Details

Name: us-gaap_PaymentsToAcquireHeldToMaturitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228
+ Details

Name: us-gaap_RepaymentsOfOtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2

Organization and Basis of Presentation
9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Basis of Presentation

NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION

Organization. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015.

Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements.

Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.

In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2

Short-Term Investments
9 Months Ended

Sep. 30, 2016

Marketable Securities Current [Abstract]

Short-Term Investments

NOTE 2: SHORT-TERM INVESTMENTS

The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,724 and $150,001 as of September 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of September 30, 2016 and December 31, 2015 was $119,604 and $149,978, respectively.

X

- Definition
The entire disclosure for investments in certain debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27405-111563
+ Details

Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2

Inventories
9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Inventories

NOTE 3: INVENTORIES

Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:

September 30,

December 31,

2016

2015

Unaudited

Audited

Raw materials

$

4,517

$

3,518

Work in progress

9,621

4,618

Finished products

9,834

5,458

Total

$

23,972

$

13,594

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2

Commitments and Contingent Liabilities
9 Months Ended

Sep. 30, 2016

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES

The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.

As of September 30, 2016 and December 31, 2015, the Company pledged bank deposits of $807 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $962 and $283, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2

Share Capital
9 Months Ended

Sep. 30, 2016

Share Based Compensation Allocation And Classification In Financial Statements [Abstract]

Share Capital

NOTE 5: SHARE CAPITAL

For the nine months ended September 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644 and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the nine months ended September 30, 2016, options to purchase 825,240 ordinary shares were exercised for cash and options to purchase 3,547 ordinary shares were cashlessly exercised, resulting in the issuance of 825,669 ordinary shares. For additional information on option exercises, please see Note 6.

X

- Definition
Disclosure of share capital.
+ References
No definition available.
+ Details

Name: nvcr_DisclosureOfShareCapitalTextBlock

Namespace Prefix: nvcr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity Incentive Plan
9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Equity Incentive Plan

NOTE 6: EQUITY INCENTIVE PLAN

In September 2015, the Company adopted the 2015 Omnibus Incentive Plan (the “2015 Plan”). The 2015 Plan replaced the 2013 Share Option Plan. Under the 2015 Plan, the Company can issue various types of equity compensation awards such as restricted shares, performance shares, restricted stock units, performance units, long-term cash award and other share-based awards.

The options granted under the 2015 Plan generally have a four-year vesting period and expire ten years after the date of grant. Options granted under the 2015 Plan that are cancelled or forfeited before expiration become available for future grant.

As of September 30, 2016, 12,717,460 ordinary shares were available for grant under the 2015 Plan.

A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:

Nine months ended September 30,

Unaudited

Number

of options

Weighted

average

exercise

price

Outstanding at beginning of year

10,134,829

$

8.20

Granted

2,363,575

13.61

Exercised

(828,787

)

0.24

Forfeited and cancelled

(133,364

)

17.19

Outstanding as of September 30, 2016

11,536,253

9.78

Exercisable options

5,887,411

5.05

Vested and expected to vest

11,329,415

$

9.71

In September 2015, the Company adopted an employee share purchase plan (“ESPP”) to encourage and enable eligible employees to acquire ownership of the Company’s ordinary shares purchased through accumulated payroll deductions on an after-tax basis. In the United States, the ESPP is intended to be an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code and the provisions of the ESPP will be construed in a manner consistent with the requirements of such section. The Company began its offerings under the ESPP on August 1, 2016. As of September 30, 2016, 1,667,785 ordinary shares were available to be purchased by eligible employees under the ESPP and no shares had been issued under the ESPP.

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

Nine months ended September 30,

Year ended

December 31,

2016

2015

2015

Unaudited

Audited

Stock Option Plans

Expected term (years)

6.25

6.25

6.25

Expected volatility

59.12%-61.65%

62.50% - 65.80%

59.00%-65.80%

Risk-free interest rate

1.23%-1.88%

1.75% - 1.90%

1.74%-2.05%

Dividend yield

0%

0%

0%

ESPP

Expected term (years)

0.42

-

-

Expected volatility

70.45

%

-

-

Risk-free interest rate

0.40

%

-

-

Dividend yield

0%

-

-

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:

Three months ended September 30,

Nine months ended September 30,

Year ended

December 31,

2016

2015

2016

2015

2015

Unaudited

Unaudited

Audited

Cost of revenues

$

160

$

35

$

471

$

54

$

174

Research, development and clinical

 trials

776

668

2,378

1,717

2,529

Sales and marketing

1,249

571

3,888

1,550

2,496

General and administrative

3,441

1,654

9,982

4,051

6,661

Total share-based compensation

 expense

$

5,626

$

2,928

$

16,719

$

7,372

$

11,860

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2

Supplemental Information
9 Months Ended

Sep. 30, 2016

Geographic Areas Long Lived Assets [Abstract]

Supplemental Information

NOTE 7: SUPPLEMENTAL INFORMATION

The Company operates in a single reportable segment.

The following table presents long-lived assets by location:

September 30,

December 31,

2016

2015

Unaudited

Audited

United States

$

11,792

$

6,600

Switzerland

3,769

4,204

Israel

1,934

1,376

Others

433

401

Total

$

17,928

$

12,581

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

Year ended December 31,

2016

2015

2016

2015

2015

Unaudited

Unaudited

Audited

United States

$

18,131

$

8,546

$

46,264

$

19,710

$

30,961

EMEA

3,519

407

6,296

994

2,070

Japan

24

-

86

-

56

Total

$

21,674

$

8,953

$

52,646

$

20,704

$

33,087

X

- References
No definition available.
+ Details

Name: us-gaap_GeographicAreasLongLivedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2

Long-Term Loan, Net of Discount and Issuance Costs
9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Long-Term Loan, Net of Discount and Issuance Costs

NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS

In January 2015, the Company entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. As of September 30, 2016, there is $100,000 outstanding under the Term Loan Credit Facility.

Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year anniversaries, respectively, from the initial funding date. The entire outstanding principal loan is due in January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of September 30, 2016, the Company was in compliance with such covenants.

The total discount of $2,019 and additional issuance costs of $2,744 are presented net of the loan and are amortized to interest expense over the term of the loan using the effective interest method.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20,22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2

Impairment of Field Equipment
9 Months Ended

Sep. 30, 2016

Impairment Or Disposal Of Tangible Assets Disclosure [Abstract]

Impairment of Field Equipment

NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT

The Company received U.S. Food and Drug Administration approval on its Premarket Approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016. Manufacturing of the first generation Optune System has been terminated. For the nine months ended September 30, 2016, the Company recorded an impairment loss in the second quarter with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.

X

- References
No definition available.
+ Details

Name: us-gaap_ImpairmentOrDisposalOfTangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2

Organization and Basis of Presentation (Policies)
9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Recently Issued Accounting Pronouncement

Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements.

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting.

In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2

Inventories (Tables)
9 Months Ended

Sep. 30, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or market. The weighted average methodology is applied to determine cost. As of September 30, 2016 and December 31, 2015, the Company’s inventories were composed of:

September 30,

December 31,

2016

2015

Unaudited

Audited

Raw materials

$

4,517

$

3,518

Work in progress

9,621

4,618

Finished products

9,834

5,458

Total

$

23,972

$

13,594

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity Incentive Plan (Tables)
9 Months Ended

Sep. 30, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock Option Plans

A summary of the status of the Company’s option plans as of September 30, 2016 and changes during the period then ended is presented below:

Nine months ended September 30,

Unaudited

Number

of options

Weighted

average

exercise

price

Outstanding at beginning of year

10,134,829

$

8.20

Granted

2,363,575

13.61

Exercised

(828,787

)

0.24

Forfeited and cancelled

(133,364

)

17.19

Outstanding as of September 30, 2016

11,536,253

9.78

Exercisable options

5,887,411

5.05

Vested and expected to vest

11,329,415

$

9.71

Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model

The fair value of equity-based awards was estimated using the Black-Scholes option-pricing model for all grants with the following underlying assumptions:

Nine months ended September 30,

Year ended

December 31,

2016

2015

2015

Unaudited

Audited

Stock Option Plans

Expected term (years)

6.25

6.25

6.25

Expected volatility

59.12%-61.65%

62.50% - 65.80%

59.00%-65.80%

Risk-free interest rate

1.23%-1.88%

1.75% - 1.90%

1.74%-2.05%

Dividend yield

0%

0%

0%

ESPP

Expected term (years)

0.42

-

-

Expected volatility

70.45

%

-

-

Risk-free interest rate

0.40

%

-

-

Dividend yield

0%

-

-

Schedule of Non-cash Share-based Compensation Expense Related to Company's Equity-Based Awards

The total non-cash share-based compensation expense related to all of the Company’s equity-based awards recognized for the three and nine months ended September 30, 2016 and 2015 and the year ended December 31, 2015 was:

Three months ended September 30,

Nine months ended September 30,

Year ended

December 31,

2016

2015

2016

2015

2015

Unaudited

Unaudited

Audited

Cost of revenues

$

160

$

35

$

471

$

54

$

174

Research, development and clinical

 trials

776

668

2,378

1,717

2,529

Sales and marketing

1,249

571

3,888

1,550

2,496

General and administrative

3,441

1,654

9,982

4,051

6,661

Total share-based compensation

 expense

$

5,626

$

2,928

$

16,719

$

7,372

$

11,860

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901
+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2

Supplemental Information (Tables)
9 Months Ended

Sep. 30, 2016

Geographic Areas Long Lived Assets [Abstract]

Schedule of Long-Lived Assets by Location

The following table presents long-lived assets by location:

September 30,

December 31,

2016

2015

Unaudited

Audited

United States

$

11,792

$

6,600

Switzerland

3,769

4,204

Israel

1,934

1,376

Others

433

401

Total

$

17,928

$

12,581

Schedule of Revenues by Geographic Region

The Company’s revenues by geographic region, based on the customer’s location, are summarized as follows:

Three Months Ended September 30,

Nine Months Ended September 30,

Year ended December 31,

2016

2015

2016

2015

2015

Unaudited

Unaudited

Audited

United States

$

18,131

$

8,546

$

46,264

$

19,710

$

30,961

EMEA

3,519

407

6,296

994

2,070

Japan

24

-

86

-

56

Total

$

21,674

$

8,953

$

52,646

$

20,704

$

33,087

X

- References
No definition available.
+ Details

Name: us-gaap_GeographicAreasLongLivedAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph b
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599
+ Details

Name: us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599
+ Details

Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2

Short-Term Investments - Additional Information (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Investments Debt And Equity Securities [Abstract]

Short-term investments $ 119,724 $ 150,001

Estimated fair value of short-term investments $ 119,604 $ 149,978

X

- Definition
Amount after other than temporary impairment (OTTI) accretion, of investments in debt securities classified as held-to-maturity, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66010992&loc=d3e26626-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558
+ Details

Name: us-gaap_HeldToMaturitySecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investments in debt securities classified as held-to-maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563
+ Details

Name: us-gaap_HeldToMaturitySecuritiesFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2

Inventories - Schedule of Inventories (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Inventory Disclosure [Abstract]

Raw materials $ 4,517 $ 3,518

Work in progress 9,621 4,618

Finished products 9,834 5,458

Total $ 23,972 $ 13,594

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryRawMaterialsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729
+ Details

Name: us-gaap_InventoryWorkInProcessNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Loss Contingencies [Line Items]

Operating lease expiration description The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024.

Pledged bank deposits $ 807 $ 133

Operating Lease Commitments $ 962 $ 283

Motor Vehicles

Loss Contingencies [Line Items]

Operating lease expiration description The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.

Maximum

Loss Contingencies [Line Items]

Operating lease agreements, expiration year 2024

Maximum | Motor Vehicles

Loss Contingencies [Line Items]

Operating lease agreements, expiration year 2019

X

- Definition
Operating lease agreement expiration period.
+ References
No definition available.
+ Details

Name: nvcr_OperatingLeaseAgreementExpirationPeriod

Namespace Prefix: nvcr_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating lease commitments.
+ References
No definition available.
+ Details

Name: nvcr_OperatingLeaseCommitments

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Operating lease expiration description.
+ References
No definition available.
+ Details

Name: nvcr_OperatingLeaseExpirationDescription

Namespace Prefix: nvcr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DepositsAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2

Share Capital - Additional Information (Details)
9 Months Ended

Sep. 30, 2016

$ / shares

shares

Share Capital [Line Items]

Options issued to purchase ordinary shares exercised for cash 825,240

Options issued to purchase ordinary shares cashlessly exercised 3,547

Ordinary shares issued upon option exercise 825,669

Warrants to Purchase 220,316 Ordinary Shares

Share Capital [Line Items]

Warrants issued to purchase of ordinary shares 220,316

Warrants exercise price | $ / shares $ 3.59

Warrants exercised to ordinary shares 220,316

Warrants to Purchase 975,644 Ordinary Shares

Share Capital [Line Items]

Warrants issued to purchase of ordinary shares 975,644

Warrants exercise price | $ / shares $ 18.09

Warrants to Purchase 888,219 Ordinary Shares

Share Capital [Line Items]

Warrants issued to purchase of ordinary shares 888,219

Warrants exercise price | $ / shares $ 3.59

Warrant

Share Capital [Line Items]

Warrants exercised to ordinary shares 950,637

X

- Definition
Options issued to purchase ordinary shares exercised in cash.
+ References
No definition available.
+ Details

Name: nvcr_OptionsIssuedToPurchaseOrdinarySharesExercisedInCash

Namespace Prefix: nvcr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Options issued to purchase ordinary shares noncash exercised.
+ References
No definition available.
+ Details

Name: nvcr_OptionsIssuedToPurchaseOrdinarySharesNoncashExercised

Namespace Prefix: nvcr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Ordinary shares issued upon option exercise.
+ References
No definition available.
+ Details

Name: nvcr_OrdinarySharesIssuedUponOptionExercise

Namespace Prefix: nvcr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Share capital.
+ References
No definition available.
+ Details

Name: nvcr_ShareCapitalLineItems

Namespace Prefix: nvcr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants exercised to ordinary shares.
+ References
No definition available.
+ Details

Name: nvcr_WarrantsExercisedToOrdinaryShares

Namespace Prefix: nvcr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=nvcr_WarrantsToPurchaseOrdinaryShareOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=nvcr_WarrantsToPurchaseOrdinaryShareTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=nvcr_WarrantsToPurchaseOrdinaryShareThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity Incentive Plan - Additional Information (Details)
9 Months Ended

Sep. 30, 2016

shares

ESPP

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Ordinary shares available for grants 1,667,785

Shares issued under plan 0

2015 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Option granted vesting period 4 years

Option granted expiration period 10 years

Ordinary shares available for grants 12,717,460

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued during the period as a result of an employee stock purchase plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=nvcr_TwoThousandFifteenPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity Incentive Plan - Schedule of Stock Option Plan (Details)
9 Months Ended

Sep. 30, 2016

$ / shares

shares

Number of options

Number of options, Outstanding at beginning of year | shares 10,134,829

Number of options, Granted | shares 2,363,575

Number of options, Exercised | shares (828,787)

Number of options, Forfeited and cancelled | shares (133,364)

Number of options, Outstanding at ending of year | shares 11,536,253

Number of options, Exercisable options | shares 5,887,411

Number of options, Vested and expected to vest | shares 11,329,415

Weighted average exercise price

Weighted average exercise price, Outstanding at beginning of year | $ / shares $ 8.20

Weighted average exercise price, Granted | $ / shares 13.61

Weighted average exercise price, Exercised | $ / shares 0.24

Weighted average exercise price, Forfeited and cancelled | $ / shares 17.19

Weighted average exercise price, Outstanding at end of year | $ / shares 9.78

Weighted average exercise price, Exercisable options | $ / shares 5.05

Weighted average exercise price, Vested and expected to vest | $ / shares $ 9.71

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity Incentive Plan - Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model (Details)
9 Months Ended 12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Stock Option Plans

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected term (years) 6 years 3 months 6 years 3 months 6 years 3 months

Expected volatility, minimum 59.12% 62.50% 59.00%

Expected volatility, maximum 61.65% 65.80% 65.80%

Risk-free interest rate, minimum 1.23% 1.75% 1.74%

Risk-free interest rate, maximum 1.88% 1.90% 2.05%

Dividend yield 0.00% 0.00% 0.00%

ESPP

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expected term (years) 5 months

Dividend yield 0.00%

Expected volatility 70.45%

Risk-free interest rate 0.40%

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2

Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation expense $ 5,626 $ 2,928 $ 16,719 $ 7,372 $ 11,860

Cost of Revenues

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation expense 160 35 471 54 174

Research, Development and Clinical Trials

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation expense 776 668 2,378 1,717 2,529

Sales and Marketing

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation expense 1,249 571 3,888 1,550 2,496

General and Administrative

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation expense $ 3,441 $ 1,654 $ 9,982 $ 4,051 $ 6,661

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=nvcr_CostOfRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=nvcr_SalesAndMarketingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2

Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($)
$ in Thousands

Sep. 30, 2016

Dec. 31, 2015

Revenues From External Customers And Long Lived Assets [Line Items]

Long-lived assets $ 17,928 $ 12,581

United States

Revenues From External Customers And Long Lived Assets [Line Items]

Long-lived assets 11,792 6,600

Switzerland

Revenues From External Customers And Long Lived Assets [Line Items]

Long-lived assets 3,769 4,204

Israel

Revenues From External Customers And Long Lived Assets [Line Items]

Long-lived assets 1,934 1,376

Others

Revenues From External Customers And Long Lived Assets [Line Items]

Long-lived assets $ 433 $ 401

X

- Definition
Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599
+ Details

Name: us-gaap_NoncurrentAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_CH

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_IL

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=nvcr_OthersCountriesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2

Supplemental Information - Schedule of Revenues by Geographic Region (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2016

Sep. 30, 2015

Dec. 31, 2015

Revenues From External Customers And Long Lived Assets [Line Items]

Net revenues $ 21,674 $ 8,953 $ 52,646 $ 20,704 $ 33,087

United States

Revenues From External Customers And Long Lived Assets [Line Items]

Net revenues 18,131 8,546 46,264 19,710 30,961

EMEA

Revenues From External Customers And Long Lived Assets [Line Items]

Net revenues 3,519 $ 407 6,296 $ 994 2,070

Japan

Revenues From External Customers And Long Lived Assets [Line Items]

Net revenues $ 24 $ 86 $ 56

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=us-gaap_EMEAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementGeographicalAxis=country_JP

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2

Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) - Term Loan - USD ($)
1 Months Ended 9 Months Ended

Jan. 31, 2015

Sep. 30, 2016

Jun. 30, 2016

Line Of Credit Facility [Line Items]

Term loan agreement, maturity period 5 years

Line of credit facility, maximum borrowing capacity $ 100,000,000

Line of credit facility, current borrowing capacity $ 25,000,000

Line of credit facility, remaining borrowing capacity $ 75,000,000

Line of credit facility, drawdown received date 2016-07

Term loan credit facility, outstanding $ 100,000,000

Interest on the outstanding loan 10.00%

Funding fees payable 1.50%

Prepayment fee percent 0.75%

Due date of outstanding principal loan Jan. 31, 2020

Frequency of payments Quarterly

Other Long-term Assets

Line Of Credit Facility [Line Items]

Total discount $ 2,019,000

Additional deferred issuance costs $ 2,744,000

First Year

Line Of Credit Facility [Line Items]

Prepayment fee percent 3.00%

Second Year

Line Of Credit Facility [Line Items]

Prepayment fee percent 2.00%

Third Year

Line Of Credit Facility [Line Items]

Prepayment fee percent 1.00%

X

- Definition
Funding fees payable.
+ References
No definition available.
+ Details

Name: nvcr_FundingFeesPayable

Namespace Prefix: nvcr_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line of credit facility, drawdown received date, Month and Year.
+ References
No definition available.
+ Details

Name: nvcr_LineOfCreditFacilityDrawdownReceivedDateMonthAndYear

Namespace Prefix: nvcr_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the frequency of periodic payments (monthly, quarterly, annual).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentFrequencyOfPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Subparagraph e
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823
+ Details

Name: us-gaap_DebtInstrumentRedemptionPricePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after accumulated amortization, of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DeferredFinanceCostsNoncurrentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum amount borrowed under the credit facility at any time during the period.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(b),22(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=nvcr_TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2

Impairment of Field Equipment - Additional Information (Details)
$ in Thousands
9 Months Ended

Sep. 30, 2016

USD ($)

Impaired Long Lived Assets Held And Used [Line Items]

Impairment of field equipment $ 6,412

First Generation Optune System Field Equipment | Cost of Revenues

Impaired Long Lived Assets Held And Used [Line Items]

Impairment of field equipment 6,412

Advances for materials purchased and liabilities incurred to vendors $ 1,582

X

- Definition
Cost of materials purchased and expenses due to vendors.
+ References
No definition available.
+ Details

Name: nvcr_CostOfMaterialsPurchasedAndExpensesDueToVendors

Namespace Prefix: nvcr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688
+ Details

Name: us-gaap_ProductionRelatedImpairmentsOrCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=nvcr_FirstGenerationOptuneSystemFieldEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=nvcr_CostOfRevenueMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
<(L M".;5/VV1G[?8Y2?T_'OZ^L+A.M+7L\/U]P+%A4 1!8HO1SS'%!=-V,F>*C!= MO#J6U#AJES9OJ2ZW\SZ/9_(!K\J!=_"7FTYH2_;H_,G&0VT1'7@3V=4U);U_ M/TLBH74AO/6Q25BJQ-$*KN!%$S-*R?2_/0B<=DF6G JOO.NM+]"JI NOX1*4X:B(AG:7W&?; M?>$1 ?"'PV3.8N*]'Q#??/+<[)+46P !M?4*S"U'> AO)!K_#YK?K7TQ//X MI/X8IG7N#\S XJ_O+&],YLFI(&6C<*^XO0$\PAK+UBC,.%+ZM%8E"=*0B3[ MB"M789WBGR*;:=\3\IF0+X2[-!B/C8+-7\RRJM0X$3,P?W;9UL&U%W'*Q'DS M(0W3Q^JQRC;KDAZ]T 5F'S%YQ"P(ZM2_;9%?MMCG9_3\9_KJRN$JT%>SP\W/ M L650!$$BO^.>(FYO6I"S_94@N["U3&DQE'9N'E+=;F=]WDXDR]X50ZL@]], M=UP9&PO=V]R:W-H965TZH&32P)I"DH'F:KJED7"55&6I/NBIQM((K>-+$C%(R_7\' J=MDB6GPC/O M>NL+M"KIS&NX!&4X*J*AW2:WV6:W\H@ >.$PF45,O/<]XJM/_C3;)/460$!M MO0)SRP'N0 @OY!J_'37/+3UQ&9_4'\*TSOV>&;A#\8\WMG=FTX0TT+)1V&>< M'N$XPK47K%&8\"7U:"S*$R4ADKW'E:NP3O%/D1]I7Q/R(R&?"3=I,!X;!9OW MS+*JU#@1,S!_=MG&P;47<3,A#=/'ZJ$JLI(>O,XGR"Y"\@ Y(Z@3_[)# M_KG#+E_0\Y_IQ87!(M"+V'U]\[/ ZD)@%016WTVXA&3KWQ<]Z&)')>@N7!Q# M:AR5C5LW5^>[>1N.D)[A53FP#OXRW7%ER!ZM.]=PI"VB!6SYP( M:*T/?[E8QPL5$XO#Z7G,;[3Z %!+ P04 " F,F)):0HC7)\! "Q P M&0 'AL+W=OQ-W5S.PL'\6(YLUV (Y\ M**GMEG;.]1O&;-6!XO8&>]#^3X-&<>=3TS+;&^!U)"G)\BS[P107FI9%K+V8 MLL#!2:'AQ1 [*,7-YPXDCENZH,?"JV@[%PJL+-C,JX4";05J8J#9TKO%9K<* MB CX+6"T)S$)WO>(;R'Y56]I%BR A,H%!>Z7 ]R#E$'(-WZ?-+]:!N)I?%1_ MC--Z]WMNX1[E'U&[SIO-**FAX8-TKS@^P33".@A6*&W\DFJP#M610HGB'VD5 M.JYC^K/.)]IU0CX1\IGP,XO&4Z-H\X$[7A8&1V)['LYNL?%P$T2\,O'>;$SC M]*EZ*!>W6<$.0>@,LTN8/&%F!//J5UODYRUV^0D]_S=]>>%P&>G+R>%_]%]= M"*RBP.K;$<\QER[9R9XJ,&V\.I94.&B7-F^NSK?S+AXB^X*71<];>.:F%=J2 M/3I_LO%0&T0'WD1VLZ:D\^]G3B0T+H2W/C;I2J7$87]\(/,K+?\"4$L#!!0 M ( "8R8DD(81]?G0$ +$# 9 >&PO=V]R:W-H965T; _@R)N2VNYH[]RP9]" M@54E6WB-4*"M0$T,M#MZO]KNBX"(@+\")GL6D^#]@/@2DM_-CF;! DBH75#@ M?CG" T@9A'SCUUGSHV4@GL8?<+D";,@F%?_M$5^V6*? MG]'S[^GK*X?K2%_/#HOO!8HK@2(*%%^.>(G97#5A9WNJP'3QZEA2XZA=VKRE MNMS.^SR>R0>\*@?>P1]N.J$M.:#S)QL/M45TX$UD-QM*>O]^ED1"ZT)XZV.3 MKE1*' ZG![*\TNH=4$L#!!0 ( "8R8DEH0@.DGP$ +$# 9 >&PO M=V]R:W-H965T80_:_VG0*.Y\:EIF>P.\CB0E69YE-TQQH6E9Q-JK*0L!-MYT*!E06;>;50H*U 30PT6WJWV.Q6 1$!?P2,]B0F MP?L>\3TDS_669L$"2*A<4.!^.< ]2!F$?../2?.K92">QD?UQSBM=[_G%NY1 M_A6UZ[S9C)(:&CY(]X;C$TPC7 ?!"J6-7U(-UJ$Z4BA1_#.M0L=U3'_6^43[ MGI!/A'PFW&;1>&H4;3YPQ\O"X$ALS\/9+38>;H*(5R;>FXUIG#Y5#^5B?5.P M0Q ZP^P2)D^8&<&\^K-&$G>ZK M/'J6%+AH%W:O+DZW\Z[>(CL"UX6/6_AA9M6:$OVZ/S)QD-M M$!UX$]G5-26=?S]S(J%Q(5S[V*0KE1*'_?&!S*^T_ ]02P,$% @ )C)B M2=+1QV"A 0 L0, !D !X;"]W;W)K&ULA5/; M3N,P$/T5RQ^ TS1 MTHC458('E9"/+#/;C))+&Q/L)V&_7M\:4-;H>4EGIF< M<^:,+^6$YLWV (Y\**GMAO;.#6O&;-V#XO8*!]#^3XM&<>=3TS$[&.!-)"G) M\BR[88H+3:LRUIY-5>+HI-#P;(@=E>+FWQ8D3ANZH,?"B^AZ%PJL*MG,:X0" M;05J8J#=T+O%>EL$1 2\"ICL24R"]QWB6TB>F@W-@@604+N@P/VRAWN0,@CY MQN\'S:^6@7@:']4?XK3>_8Y;N$?Y5S2N]V8S2AIH^2C="TZ/ MY?%,ON!5.? ._G#3"6W)#IT_V7BH+:(#;R*[NJ:D]^]G3B2T+H2W/C;I2J7$ MX7!\(/,KK3X!4$L#!!0 ( "8R8DD>9/$MH $ +$# 9 >&PO=V]R M:W-H965T6CFM&\V ' D5!M)2E*6YU^HXD)G=15K3Z:N<')2:'@RQ$Y* M+("$Q@4%[I<3/(*40<@W_KMHOK4,Q,OXK/X]3NO='[F%1Y1_ M1.L&;S;/2 L=GZ1[QOD'+"-L@V"#TL8O:2;K4)TI&5'\-:U"QW5.?[;%0GN? MP!8"6PGW>32>&D6;W[CC=65P)G;DX>R*G8>;(.*5B?=F8QJG3]537=RSBIZ" MT!7FD# L858$]>KOMF#7+0[L@LX^IV]N'&XB?;,XW'PN4-X(E%&@_'#$:TQY MTX1>[*D"T\>K8TF#DW9I\];J>CL?6#R3-WA=C;R'7]ST0EMR1.=/-AYJA^C MF\COMAD9_/M9$PF="^%7'YMTI5+B<#P_D/65UO\!4$L#!!0 ( "8R8DEK MPU:2H $ +$# 9 >&PO=V]R:W-H965T6CG-"\VA[ D3U# M95NFN-"T*F/MV50ECDX*#<^&V%$I;OX=0.*TIRMZ+KR(KG>AP*J2+;Q&*-!6 MH"8&VCU]7.T.14!$P&\!D[V(2?!^1'P-R<]F3[-@ 234+BAPOYS@":0,0K[Q MWUGSO64@7L9G]>]Q6N_^R"T\H?PC&M=[LQDE#;1\E.X%IQ\PC[ )@C5*&[^D M'JU#=:90HOA;6H6.ZY3^;(N9]C$AGPGY0GC(HO'4*-K\QAVO2H,3L0,/9[?: M>;@)(EZ9>&\VIG'Z5#U5JX=-R4Y!Z IS2)@\818$\^H?MLBO6QSR"WK^-7U] MXW =Z>O9X?9K@>)&H(@"Q:E0/OX!:?4?4$L#!!0 ( "8R8DF/E[SXI0$ +$# 9 >&PO=V]R:W-H M965T6C&-%\V [ D4\EM=W1SKE^RYBM.E#< MWF$/VO]IT"CN?&I:9GL#O(XD)5F>90],<:%I6<3:FRD+')P4&MX,L8-2W/S; M@\1Q1Q?T5'@7;>="@94%FWFU4*"M0$T,-#OZM-CN5P$1 ;\%C/8L)L'[ ?$C M)#_K'!Z?U%_BM-[]@5MX1OE'U*[S M9C-*:FCX(-T[CJ\PC7 ?!"N4-GY)-5B'ZD2A1/'/M H=US']>=Q,M-N$?"+D M,V&=1>.I4;3Y@SM>%@9'8GL>SFZQ]7 31+PR\=YL3./TJ7HL%^MUP8Y!Z *S M3Y@\868$\^HW6^27+?;Y&3W_GKZ\*@- MH@-O(KN[IZ3S[V=.)#0NA(\^-NE*I<1A?WH@\RLM_P-02P,$% @ )C)B M2:ED!6:C 0 L0, !D !X;"]W;W)K&ULA5/+ M;MLP$/P5@A\0ZN&DJ2$+B%,4[:% D$-[IJ651(3DJB1EI7]?/F3%-@SD(NZN M9F9G^:AF-&]V '#D74EM=W1P;MPR9IL!%+=W.(+V?SHTBCN?FI[9T0!O(TE) M5F39 U-<:%I7L?9BZ@HG)X6&%T/LI!0W__8@<=[1G)X*KZ(?7"BPNF(KKQ4* MM!6HB8%N1Y_R[7X3$!'P6\!LSV(2O!\0WT+RL]W1+%@ "8T+"MPO1W@&*8.0 M;_QWT?QH&8CG\4G]>YS6NS]P"\\H_XC6#=YL1DD+'9^D>\7Y!RPCW ?!!J6- M7]),UJ$Z42A1_#VM0L=U3G_*8J'=)A0+H5@)CUDTGAI%F]^XXW5E<"9VY.'L M\JV'FR#BE8GW9F,:IT_58YU_S2MV#$(7F'W"% FS(IA7O]FBN&RQ+\[HQ>?T M\LIA&>EEZO[P^+G YDI@$P4VRXC%S1$O,>55$W:VIPI,'Z^.)0U.VJ7-6ZOK M[7R*A\@^X'4U\AY^<=,+;*@=H@-O(KN[IV3P[V=-)'0NA%]\;-*5 M2HG#\?1 UE=:_P=02P,$% @ )C)B2=8.([&\ 0 >P0 !D !X;"]W M;W)K&ULA53;;J,P$/T5BP^H"4E(&Q&DIJNJ^[!2 MU8?=9P<&L.H+:YO0_?OUA5! 2'G!GN%<9L0,62_5IVX #/KB3.A3U!C3'C'6 M10.,4._@^:WI2-.[S?U5]^MK?Y"-+Q( M]H>6IK'%QA$JH2(=,Q^R?X.AA;T3+"33_HF*3AO);Y0(3 <'5?LET*B0G3!A M#,;LN&?/B9^N;WB>M:2&7T355&ATD<;.J!_/2DH#MHCXP;;:V#_!&#"HC+L> M[%V%Y0B!D>UMU&PO=V]R:W-H965T0'* YQNE7D6&I: MK=K#2E4/NV=BCVU48+R X^[;+V#'B:-(N01F_/V-@.0#FB_; CCRK:2VNZ1U MKMM2:LL6%+950H*U 30S4N^1YM=UO B("?@L8 M[,6>A.P'Q*]0O%>[) T10$+I@@+WRQ%>0,H@Y(W_3IIGRT"\W)_4?\9I??H# MM_""\H^H7.O#I@FIH.:]=)\XO,$T0DQ8HK3QEY2]=:A.E(0H_CVN0L=U&+]D MCQ/M-H%-!#83GM(8?#2*,5^YXT5N<""VX^'L5EL/-T'$*Q.?S<8R3C]VCP5+ M5SD]!J$%9C]B6,2<$=2KW[1@2XL]NZ"S^_3U5<)UI*]']Z?TOD!V)9!%@6P: MD=T<<8E9WS?97)EL%@+939,E9G-E0B\.3H%IXOVTI,1>N_&$YN[\!)Y9//@S MO,@[WL O;AJA+3F@\]W 0 0P0 !D !X;"]W;W)K&ULA93;CILP%$5_Q>(#QN:2D$0$J4-5M0^51O/0/COA M$-#X0FTG3/^^OA :$)IYP3YF[\TZ8%,,4KWI%L"@=\Z$/D:M,?T!8WUN@5/] M)'L0]DXC%:?&ENJ"=:^ UM[$&4X(V6)..Q&5A5][464AKX9U EX4TE?.J?K[ M#$P.QRB.[@NOW:4U;@&7!9Y\=<=!Z$X*I* Y1E_B0Y4YA1?\ZF#0#W/DV$]2 MOKGB1WV,B$, !F?C$J@=;E !8R[(/OC/F/G_D<[X.+^G?_/=6OH3U5!)]KNK M36MA281J:.B5F5QA8T+/$NF_16=K]I(?K=$B-/W,';"CT.XLR.C;=V0 MC(9D,L39AX9T-*0+ PYDOJ^OU-"R4') NJ?N8\<'*U@R8)FC5%-5-L)@FV *L4R8(B\?YTI,@_#T@7 :D/R$+ ;LXH M0A=!DGM)'._S)%N353/9AA 2?TZ3+6BR1QJRCI/-<;9D'64! !3!0 &0 'AL+W=OLH^I) M#*PW=VHA.ZI-*2] #9+1RIDZ#E 4):"C;1\6N5M[E44NKIJW/7N5@;IV'96_ M7Q@7XS&$X7WAK;TTVBZ (@>SKVH[UJM6](%D]3'\! ]E8A5.\*-EHUK, \M^ M$N+=%M^J8QA9!,;96=L$:H8;*QGG-L@\^->4^?>1UKB@R8!F XS_:<"3 6\,P).YOCY338MOR MJ[<"15D.;C9HI7GQ&N0U>XIRI2"S!!B 70JTH4#.CYT?)L__#\"; .P"8@\ MHS5D[]OPFM1I8@+3/5&Y%&$"'T")-RCQ"@7NHGA-XC19@G9%Y5(4)X^@D T* M6:&@712R1'G&\2[*4D1B\@!*LD%)%B@9WB5)%J\>X2S=Y2V7*HA)%F]8P.+_ M'^B%?:?RTO8J. EMMI+;1;40FIFLZ,GTU9@3;BXXJ[6=IF8N_:;WA1;#_0B; MS]'B#U!+ P04 " F,F)),O7H/SH" #=!P &0 'AL+W=O@ MVIBUG=#]^[4-H=A%@KS@"W-FYF".3]XR_B%*C*7W24DMMGXI9;,) G$L,47B MB36X5F_.C%,DU9)? M%PC$XFB)( AF$:4%35?I&;O3=>Y.PJ257C-^Z)*Z6( M_]MAPMJM#_S[QGMU*:7>"(H\&.).%<6UJ%CM<7S>^L]@LP>)AAC$[PJW8C3W MM/D#8Q]Z\?.T]4/M 1-\E)H"J>&&]Y@0S:24__:D7YHZ<#R_L[^8=)7] Q)X MS\B?ZB1+Y3;TO1,^HRN1[ZQ]Q7T.QN&1$6&>WO$J)*/W$-^CZ+,;J]J,;?N)!NG3!AL%YYI$,7LJ&6&6 MYG-UN[<"@B@/;IK(PNPZ##08," "Q3XI 6V)'1R%PRF!O85(YA4B)XG(Q$=] M$O$\0>P0Q(8@[@F2R:]@8])YD<0122R"E2U2=R(=9F4P63B)V8\Q((KFC:2. MD=0RDDT:24_3@UP[!>L'!6Q@8SHN MT"VRT*)84$/@6YV"1U,%T*6 EHO),]WUH+0#A7")D%N.(+*$%OP8P"U($#^< MKEMN(%F2;F*E^^T?#$:W*<7\8KJ,\([L6LONVAQVAT[V#,UM_ 4O\@9=\"_$ M+U4MO .3ZDXWU_F9,8F5C?!)V2A5KQT6!)^EGJ[4G'?=IUM(UMR;Z=#1B_]0 M2P,$% @ )C)B27.& ZR' @ Z0D !D !X;"]W;W)K&ULG5;;CILP$/T5Q <$/-Q7!&FS5=4^5%KM0_OL)$Y "YC:3MC^ M?6U#6'"1XO0%;#-SSEPX,'E/V3LO"1'.1U.W?.N60G1/GLFP>S/CM2T MW[K(O1V\5>=2J .OR+W)[U@UI.45;1U&3EOW&3WM )2)MOA9D9[/UHX*?D_I MN]I\/VY=7\5 :G(0"@++VY6\D+I62)+Y]PCZR:D=K@Q_CSEYH?6O MZBA*&:WO.D=RPI=:O-'^&QESB!3@@=9<7YW#A0O:W%Q M9)ED.T0YV,3:)H4(0O\^3V3P1 N>=)4GFO$$49C<9XD-EGC!DJVRQ,MLXCB[ MSY,8/,F<)[ H1VH I(_V+3, LD4$:#73;)8I@!\@"Q[DFRKP%TRPRC0:I4/K M-I%%2=$_5AXRI8="BQZBN?BR)(I#FVA- M]:'(IHG1K(DHW?@V7305B!82#"P^:<@4%TH>+JTI+Y3:E#:=?PG2%)!-PJ80 M4693VNQA?8 I1%@*T:(L8$H,T*.5!5,Z !8J'8W&ES;RX\#\EGNS7W%#V%E/ M'-PYT$LKAG_N=#I--<]ZJ/$^S8N\PV?R [-SU7)G3X4<"/0L<*)4$!F(OY&O M="GGKFE3DY-0RT2NV3")#!M!N]M@-4UWQ5]02P,$% @ )C)B25@ R0,( M @ & 8 !D !X;"]W;W)K&ULE97=CILP$(5? MQ>(!UF ()!%!VFQ5M1>55GO17CLP"6AM3&TG;-^^_B$LT$A);X)MSGQG[(R' MO!?R7=4 &GUPUJI=4&O=;3%690V'(7D5)NI/&'52:"5"^(,DS!, M,:=-&Q2Y6WN512[.FC4MO$JDSIQ3^6!T?*5_==LUZ1^H@A?!?C65KDVV88 J.-(STV^B_P;#'E866 JF MW"\JSTH+?@T)$*[]Z*4B MW3=*%T;IS(C<-$HG1@_L)5M89#.+^#Y@O0"L__B[('?/ZY0=$#Q3&(ANH@690EZ?+D\.3F6I:14Z"&WZAVL=1R$TF%3")U.HM6G3XX3!4=MA M9L;2-RX_T:*[]N'Q8U#\!5!+ P04 " F,F))Z81>GJT" !_"0 &0 M 'AL+W=OT*+)0WWK^)$V,R>&^; M3JS#DY3G51R+W8FU5$3\S#KUSX'W+96JVQ]C<>X9W6NCMHEADN"XI7475J4> M>^FKDE]D4W?LI0_$I6UI_WO#&GY;AR"\#[S6QY,[?=VR3M2\"WIV M6(=/8+4!9)!HQ8^:W<2L'0S!;SE_&SK?]NLP&6)@#=O)P055KRM[9DTS>%+D M7Z/3#^9@.&_?O7_1Z:KPMU2P9][\K/?RI*)-PF#/#O32R%=^^\K&'++!X8XW M0O\&NXN0O+V;A$%+W\V[[O3[9O[)B]',;P!' S@9H$0';D ZS,]4TJKL^2T0 M9SI,'E@I>3\X49X#%9O079V]&;U6,"5E?!T<69J-T4"M 9,B5MZ]"&@C-G!F M#F'VV %R8D3: 1IC+!X[2!T'J7:0&@=98B?9F2B-!ILD$X!2 A>0,H>4623@ M)64S$D089?F";X(=$+9 T O",] G DE.\L>@W 'E%@AY0?DWH@F3WN M.HEG!V3+^J.^!XA@QR^=-"?A-#K=-9Z@/F _Y%5YID?VG?;'NA/!EDMU3.L3 M^L"Y9"JF)%*3>U*WH:G3L(,G.5?T!4$L#!!0 ( M "8R8DE:WQRZE@( *H* 9 >&PO=V]R:W-H965TUY_%]21K,G^B9M/*?(V4-%G+* M3AX_,X(/.JBIO<#W8Z_!5>MFJ5Y[85E*+Z*N6O+"''YI&LS^;DE-;QL7N?>% MU^I4"K7@9:DWQ!VJAK2\HJW#R''C/J-U@6*%:.)716Y\-':4^1VE;VKRX[!Q M?>6!U&0OE 26ERO)25TK)7GG/[WHQSU5X'A\5_^FMROM[S G.:U_5P=12K>^ MZQS($5]J\4IOWTF_AX42W-.:ZU]G?^&"-O<0UVGP>W>M6GV]=?\D?A]F#PCZ M@& (0,O_!H1]0#@W(.H#(B/ Z[:B#Z+ F'G[%Z/-!:XDR)2&5'[I[K MJ3[?;O6:!?$B]:Y*"##;C@DT@VQ$,286JP'QI &KBP"ZV :C^,!VAWQ,Q(G5 M!!!9/#81&D<1ZOBH/XKXL4!D"$1:(.P$(O^QP,(06 '2VLR(&,]B7P&4TPQ MDV9CPVP,!%96LX!9^E:SD+$_7Y )'IM=&F:70""TFH5,9#4+&>OK4DPQDV83 MPVP"!&*K6Y6$T,K,CS?ZHC>$G71K MQ)T]O;2B^]X-JT/[]1RHCL!8WZ)UWC51'S)9>L8G\A.S4]5R9T>%[#=TJW&D M5!#ISG^2IU#*QG&8U.0HU' IQZQKI;J)H.=[9SBTI]D_4$L#!!0 ( "8R M8DDAH!GE\@( !$, 9 >&PO=V]R:W-H965T]V&O 1L MSCDS.U M/!Q%MQ'-\VC@[?F@2UI5G9*,_+L7O<7LB.;]57VCRI7IOQ6<+EGUJ]R)H\PV M#H,=W1?G2KRRRS?:UX ZP2VKN/H-MF M ?"$,=/2'I"K_DS"DYLTH>(3!Q!":/F@YBMT_%(VSO0;I20OPOO07"[C?>.V^!8$*\J+6% M @00K_VV%H(CFA_XTJ:!5?Z(K@.@*P$?/@2W:M/6." MRK3C)WEL1SF?#XN*[D5W2^1]JR=6O1#L=!W AW\!\[]02P,$% @ )C)B M2=5:N?LP @ ]P< !D !X;"]W;W)K&ULE57; MCILP%/P5Q ]K\CK$WO?AQV/JA]D HV4LM M@=5P(16A5"NI-_\91?^_4Q.G\ZOZ-U.NLK_#@E2,_FX.LE9N0]\[D",^4_G* MAN]DK,$XW#,JS*^W/PO)VBO%]UK\;L>F,^-@GV3A2%LFP)$ ;P00?4I (P$Y MA, Z,W5]Q1*7!6>#)WJL_VVP47"N192RIXH19FGBLKN7$N9I$5RTT SS;#'0 M8I80U0P1WR"!,K#H CHNH.&CT45V7P Y L@(1*- /C?9V3(L)C48D.8P6T)5 M,Q2,,W#?3.28B29F4!C>%X@=@?C1.!)'(%D1A\4DME"=QV(<4U22K"DF=;RD MLS16Q)DY MFC:>2.0+XBC7Q2)TJ315 U!44PC.Y; :';;^$L#KA"XD/+@D<# M 6Z_ ;@BDA$T?B$YBA8SF:-4="OLN-T+T"P4M$+"[3D0/1R*VW4@7A-*/#D? M(H26,YF!/GSSP>2([O&)_,3\U'3"VS&I3GMST!\9DT1)A4]*JE:W\&U!R5'J M::KFW-Y+=B%9?[UF;W=]^0]02P,$% @ )C)B2?0G['.Y @ 0@H !D M !X;"]W;W)K&ULE5;=CJ,@&'T5XP.,((K:6)-I M.V;W8I/)7.Q>TY:V9E2Z0J>S;[_\6(LN63LW"GC.^;[O@$!^9=T[/U$JO,^F M;OG2/PEQ7@0!WYUH0_@3.]-6?CFPKB%"=KMCP,\=)7M-:NH@! '#:E:O\CU MV&M7Y.PBZJJEKYW'+TU#NC\K6K/KTH?^;>"M.IZ$&@B*/!AX^ZJA+:]8ZW7T ML/2?X:*$2$$TXF=%K]QJ>RKY+6/OJO-]O_2!RH'6=">4!)&O#[JF=:V49.3? MO>@]IB+:[9MZJ5:O?5_,E!3W-30A[0C@0ACAN NH)Z$Z(_DN(>D+T:(2X M)\2/1L ] =\)6)MOS-)6;X@@1=ZQJ\?/1"U N)#P3HE(94_ZRW57SZ 9_2@0 MB/+@0PF-,"N#"34&)R[(QH9 %Z*T$7$V0 *9HS/1<)SH*K3XH2O"VD;@U)GF MK,C+O$@Y$HGG*T$3RY'F(\//TGF!:"(0:8%("R1@G&-KW#*0Q,2 .(E+C2?&Q53P"8%X 3P3P5^U/ M)@+)O/T&@LWOD$($G?;;J#1V&[NQ01&6_COM'P7,$NA,J[11"&08SA>?3HI/ M1_8_L/JSB4#V5?LAF&Y98'X">DQ?:@PSYP3T*+,>(Y X)V DAG(9H1)G=:6(TP\ M+3BPSKN&=D=]->'>CEU:86H<1H?KSW.HSLO)^ HNUM QOH&+%W.YNULFY"FM#^@#8X+*I,&3W*=.\D(W=&IZ$*J9R'9GKCBF(]CY=F,; MKHW%7U!+ P04 " F,F))SL]5HN " "_# &0 'AL+W=O>VSSC)UF5#7MN M/7&JZZ+]O605/R]\XE\&7LK]078#09X%8]RVK%DC2MYX+=LM_"?RN(:D@VC$ MCY*=Q:3M=^SOS< BS!\ 0 &/ J&,/H$, O0;$_PR(AH#H&A#II>FGHA=B M7<@BSUI^]L2QZ,J#/"IXVY$H9D_-7NBN7M]^]#VG89(%[QT1PBQ[# R8N0VS MFF+(B A4!M8T *>Q!"216B6F&+ AUHB%A+?3H,9J4$U !P*'>40&0:0)HH' MFN428^AMD9DA,D,$$19I>I$>D_3/(QQ^MZ5B0RI&4C.K5#R1@IFK4F(H)4@I MMBFMDXE2XJPT-Y3F2,E:\BN,F=\620V1%!&DMNFLTO][1B0T/1Q.Q2"T&Q2# M'&J;?-HK"**P5O?* #F4-P%3!Q!%9-?!H)F#CNEV0A%%;-?!H,1!Q]P4"'(\ M_&4#Q:#402F93J:($M3A\(&TZ@0WKNZ8'H0B(,W,(A&#CJF!P'9BSK8"TQ[ MP=UO4S"= Y'+;!&(Q@XZIG, .\?!Y& Z!^YV#IC.@<1EMMA>YJLIF!S_:M;N M]3E:>!M^:F1_SAM'Q[/Z$^CCXQ6>9\=BS[X7[;YLA/?*I3J$ZO/GCG/)5!;A M@UJP@_J:&#L5V\FNF:AVVY^O^X[DQ\OGPOC-DO\!4$L#!!0 ( "8R8DF$ MZ9<5V0$ % 9 >&PO=V]R:W-H965T[H-5ZV&*LJA8X50]B@-Z\J87D5)M0-E@-$NC1%7&& M21BFF-.N#\K"Y5YD68A1LZZ'%XG4R#F5?_? Q+0+HN"2>.V:5ML$+@L\UQT[ M#KWJ1(\DU+O@,=KN +& M+)$1?C]S?DK:PN7^PO[LNC7N#U3!DV!_NJ-NC=DP0$>HZ_6R;_)PW/9[0)R+B!S ?'&O9"S^9UJ6A923$@- MU/Z[:&O@TI(89F2\*1>Z[GWV5,;QMP*?+-$59N\QQ&&B&8$-^TT)8T<0>X])>)\@61$DCB!Q!!FY[K'W)CTD&POEN(T>2_FT^1<+HQJ@!DLW[T'H, ML"6J38\NBVP/O(/]46(ER9HN5G'JD%K&_/!K#+#[Y>S,ZN M8$,ML;(R(S,C([ZXDM^%820^;5TO_..WFRC:G;Y]&RXW;BW'^U;$GO.W6)[YL1?]\=MNK_OM]]^% MSO??1=^?^\MX*[U(6)XMIE[D1$]BYG&?CN^)A@@W5B##[]Y&WW_W%M_A]\;B MRO>B30COV-+./YW+75-T6W71:;4'^8..'2 RP\#7UK8PO6O_ 0@(I+B,"CR@>C@#H@,@> 9\\DG\ M23[EVYW%09!?@JKE;#3:G4:W73'4A>/*0)S!>VL_*(QS[7L-:[F4T 9:V-RZ MBFA_NP4>FT?^\F-=S.D$B)LX"B,X)K"0A3G<7)]/K^?3KJMG?!B < ]A() 8GO\-9U84GHWS3 M"T>ZA]K,Y0,PC;>48F<]B57L%9C])MH Z[F^M^:E+*>;YW:PU/AYTHI?THIU0_I06"4Q'$LGJWLEOB.M:]XSI1R=ZE^[*/ MOLMD_JYO>;3@PE\)&\X_ZB_S"YF_YPFS%$9QL MYU=I_QNM)CS!A?53(78J1OWZ<-BO=UI=<1)[5FQC!V^2'J#YJ LM1O7^J)U\ M&@E0:I'&$GEY'S(-V"/)[8,!QHPV;6G9KGV98CBYM?"(;63D@"I\ XKBE7A; <#:G?T(+(*I M$V"X68&J\^ P.0@;_- Y )^4[@M9]R4LMK]9@>GRS3]H_CRJ'V;8HYKZGZV5 MYPOXAT_HS86XN9W>318S:'"T?NX>C8$+VGOF 0M+D>Y2]7Y<@W@,0 %Y<9$) MSD ZHNRL>C[;PM$*: !HM)@;%T'0]96P"8 %A=6#)+JZ2M%7R44O@>)CW"2 M]):]A>YPV5#"E!]O?P_AU9,LDRCI(=+OEV*%2US$>PF&B@3FH5V.K$_ZG0H^ MV-,"M[^,G'=6Z"QI.K;CQBCF/-52P#2$G]$6^9?_+)WU!M^Q$-BLI?!BDMS M)'Y.S<0A-$/9#"(WIL6YWS]RZ8"9@Z=/8_8 @L:\!7D*!W;V\Q3:P-_3HX]B M1MRI147#\2RC*-2#ZK-V4Z%=$I""&U7$VAO+6^-N"]QU9^TIK+1\$F@ZA2Y; MK);]U[@"7M_B6-!$XYF=:WD5*.R@YBM*O=PZ_S !'#*'IZ4:[.@E)WH*"PC\ MU)BXKA^529B_M LK/I=H!(@?Q6T@5Q)6S6:KJ_!JI[A9FE/GI0HR]W@_9<;H MI9WEGQ]+M@%R;A7(.:L .94M]U->_=[1-!I0B0] ]M1<'H!7Y^7PZIWE$H(' MP&@:LKVJ=B= .Q2(!4KYC$6^D,HX*%H-GV2P=$))4FZ' MS5D=/%H!.CB>W=ZDN"#7M?T"[W*34F51T>QY/3.N5P3"BPIT4P,91:Y,[%H" M 0 (&-$9/8#2?W!LU ?8@RVWG@-[RDNZAY8S'^SX@"07]+5+V$SU"IN1TR:? M)6^54#R2OPI0ZPC^JGR'C9UJ5V9%WWO?N>:9)1:N1A/8R=*-R4\7PQX$CP'@ MY4"L)/8*;[P"BVK8ZQS='[[2;8^_LG[(VR@']+*Y$DJOE![F(OW/1/-GD_D/ MXN+RYL_'XW?RD:U<_S$4J\#?&EC10IN5#/^"LI^D6AP9/)!+'U"A*U,0!)_B M[^1XT^CIJ*[/)1P#0)B,%A#@;OT@F&L;QC&&"9_L,53?PKE/M M/ZP8S3_*05>Q(M%>CYI)F/]\[UK%F'*/CZM^@0L1/Y M *??QF >6JQ:=Z6^VGUO'&#K2G[;Z\*^#?REE+::Q=:*X@ C :0CC_&0FP0> M]T:RW(GVO7\2)VKMWY0NY*'%7[&->F#Q,S-UCD,JV9?_7QG=0?0!*PE"8^UX'DX(011\L*-XX;/[D0@M#_9 @;,5[,^TL27$%9["C D?QKNK*7\X[<[["EXD-]^?WVSF(KVJ;BY>S^YGOT[ MN1/)5?QN,I\1N+J]F\X!:/&3#(5-@<'4,PJF*D^^ 0@=(&:9S $A=GP?.K9C M!:0.<-%__^T_T6ZSO*???_NO-V"EA.1_"G8^QSM1CT&S=Q9(_T=G^1'7[T= M[_))15S@;, +SLYRW2?8^+6U3M\R''EU$(Y>O()%05J)>?SM%DTERS70P&)! MD;40N8"ZB(#/(WW<:2(BB@%"A$TQ=U X0^R8G@^:C("3CP.[^M91V![.40C M_"#D"VLC5S ,(S)%*AWF'''T&5A 6\=]4JK'CI?Z-1>LCR!+MP66$JRPT@,I MS6@D*?L(5C^PG) \C&QWT[" ;H+8(?$-IR'T/4^Z38"BV7D%*#1RQ*9R4O M+0#K@UU52C?\,8U1X>-O:-DS[WGB1PL&5A_VF\9I#!//'@'$0)\6)!>@%1/, M_ETPFCSV"!@'957LB0X&'"Q)1&,G,7ZHY)Q> R)L_[%CVD%H+?4[NB]\0KX_ MU"=HEV^L!Y3*$H =!D(\[*TI9KR8R*WJV!@4_/[;/T(\:W .^=SAL^?,$NQQ M%U46GA/#^5@7CQMG"7(?CJ^'^30)Q\8!B7#8!0_QCT3%#BP8H@&/'$>^@Y*A MQ,X0IKPUYF;QM,+G$4]L0_D^",,>G6@C/C3G3;'F (!+BXV!2%NO.ITU%F&( MO8FY)Y-;DH8!ZC8$#.EZXIG86A^!:P%E;9F-$:X#'MHJ9TJT <:V6.\3JVQY M=V%N(&T2Z?C,F2FC(.5<#V0;2,$)2%1H"53&+O%=[**+'88/$(_*@*4> ;!H MXX<&Y;3F7X4,Q*XX[CV@&VDIS[_WU]@C/N9]R/.HY7DQN::/&1)?YI$0\4G8 M!'48$UUC=CWAKN]HP1%B70!#B':K\:=$KZPX;^@)\X8D!N**@6AQHA0D_8%O M$U.LP&RWTRG-\0 0].-D.(WR,.P(*)E\8:J?^?2,>H"/KC#2)7B@ ?-^Z*S9 M?X91+X,W87&6U/MNYSKI?%7<_?AES NJD$QOUP_3/I.)TBG7 V+7#B@$+P(^ M2G@WB?RS+'.VATEH"LSXH6YFG%LP2><)IH('OR\5M23E+N1]$*,8P55B29:* M>./=.89RK0!4V#L?_J%#?#&9OZ/5=@I#I3"9GXE1K_-&RS]T "%K*C@T8Z%K!S:2$[!K,(9.7 6\;N':$J($=->436@;AE)Q'/X.>$CI8D\^BE#-+Y5? MNCWV!;L*NP_ &R4XP@<+8ZY+T.ZALZ(CK2@!#I$.&5B\F4!E8!CWJA6[TWTO MNQXXH<>-I+?A+3BZ]-QECPZ0;9P;O*!*UA_G1 M 05E2[3['$ 8>C0>0KE-<"BU(;^B]:9I!="04)!ZK+;0 Q@@.$MH(A##8\!3 MN-C_/5L/"/8(EZ*YJ8X4#9E-6P&YK(A'$@"?^7HS;.W_@_VQ1( #-/Q5 XQ* M]BZQA%73T&X75J2HD=6JD_BQ$BK6B-*(,IA9]"A=F-:6LPP + (K("V*7%#& MV95LBLO23K/]^ %-B)?]/@% D@PV$%Z CD&48B3ED\,.B'4,L@#99E7"-X>X M%3B:N)5'H2[4U..007K"O*QP89FS.#^U2ZNI"C%UH!$][=0F LJQ@00X9ZEM MKT\#A4ORDU#2 89&O"YM5E!XU!\42?:9U&8MHE+J)Q)U_4-(4)G!FQML:'%+,?GBR $"[%,/VZ,VI MF&W1KI&)PSS)W>,8WCLZR+?*$92*=@7P=68VX4&##(W*\"!)S-DE^T@%"+67R7HD38&F$)V=)%"HTK<)Z7@["2(K&5&!S0AJ=6=/_RS9B]FT6W"DHA^Z6B7^PF5F] M#)>20&+LP8Z;T' ?62N41@FBPJ0^YH_$]@&\H%]#WB98@> TVV533+,\[X0I MVU/4 1E>]9%(T#FD"/IDXW3@$@T_]'?A/ELODJ!>2L MSPG84YA,BR!@+?UU M8.TV'.;,+!R\!/H.L "QAZ4R,,CE<64]57#*M=]46]?Y+&ZYMH+ ?VS,E^@] MR4A5B]R9N-9H"$T!,-F.:>@[(2T:V488G 0(ITP;]B@$.;B'GR8<@ %4345= MW -C,< K 5>).QH'"LRA%8)C MF]V6]\K9K**3@,(^X>+$3KBA3RBF9A9F9")V0! WU_2RTE,80NK;/C#0KEO8RTP?M>I MV571H YM,:R"CPM3O U!N\B'5%*;V:^-@5Q42DQ>GI"4A6SB,)KY)/ M0_D28H^,D-"W0NS*K3&ZXHJF"HC06ETL@VWZ6@4)E@$I.">Q#O0$!P,6#3N M\7?R#;)G/TBE!*_%1KIV(_(;2?I'F%"N#5+*>2)?JL(<[ %BGY23+*<:C,9( M=AR'*,\-27S!%&'@;+_VN#[L<(#L5;O?JK=:;;5?GU> 5=?^=[1]5>3 -O-! MG]P<=\Z4,&CJ3.>0H):Y68])="BLO:KUZOWV$/[M MPK^CVI_]X",K23!F0+[48+&BH/#TU&W5^O7>_U1C?+[ MH:-.%_:T [\ TNR/"ZG8%!V)4I1QEJJWR^I4,_.MB?D6!4B.YXO>J:BLM,Q4 MR=+>KZRE5K?Y&$J@_(8VY]Y2W!_=?CE'H;!@&66*%;10EU2 AC69;NJ^!DX#S/L*AV&$-(:<7CUI#=?*[W;RPB7SV4/!KZQCS&0AL9'.VL"NU M(I1GK^=M[!59:!J(&!VIT +UGT0#8W<%@E>#K?P1Y$U<&MR'TQ@/.CR-SJA[ M0'AQLG)%#0<_9)=FQB,Z8?2B MBBSE[&>KO[CO];2, 38JB=9T.JUZ%[@B7P66V#RZ)@*@'%MMK[K-_IC%F7Y( MH A-,I5,0!:-D698,4@]6UUADC4>]NN#'FN9T6A4[[3'Y21FZ>/=;8^:Z##& M_25:DR*U/,>R3 8,B4@,[?PCYS,&Y3SH#O,4-9^Y(;J$PYSXJ-.O=WJMXF0S MZTW )6VE!DF/AIL11M^6E,89^N)FE3UY=\HH/*/J3SJ@]V;(X> I&YSJ MPKC9]1DH%2Q.O+V<7..I37>Q*#3):)=V&HV_V7I@E(6YJ613$_"3-!LK^0@3 M3M!+DO36Y9E@3A9.$MLTQ0?2()'Y8I:D)69847A$*P^,E]$A489AII9*Q2+" M&'.%0C-_6I]7TW6K/S.;46@H]IPHUU9]E&;[,N_B>,S!Y& T0RQ,"R^+YN\U MZ0&ML#/S-K*$*/$*3%<_#AJ4(Z+-/I6DJ@J"4:M&TJ,TDE!%/:7O)06(K ?+<1.+;Q53@J4:N$I_ MUT6[4Q^VA_7>H$)*9'NE[LK(QCAW&&^W^+I2G(BJXSQ4(C6JXY;H0-IO-NCL MZ&)V,/SJ*6GH&%8Q+ ;@]]/:]7Z9:2#AZ[1VF7>G5BAOSJJ%FG&3#]H,F61I M9(!:NU5O=WOU46<,N'?4[+1J[WG#:YUZ=P#"=-@'.-P[@WJGWZV- MF\.1'I?V54^[7Q^-@!':[5J_V>K7?I:A'CUQP().0/['[KJ=,;3MPP2APW;M M2'%F&94IQ&6ICB%'*1K:T_DM9]VA.]5;PLG#/2 Z/")8NL[:H5^2$"QE") K M1/B/<'8QG%3*>3D6UZ,C/P5^O-Z@,S,I3=U93X%/R25HW]#)95<_'? &51>R MLW]6DM;**X"SR8=0[LFM#5--UX)D768M8 G2B"C:F9;FL;GD;+I>IZOG2+GO M'J6Z<;C@S+=EDC!'50LAT[]*J=(9'.C_C53-%L@Z$+(>E57J;*\TQRWC5L.< MYI@2H99IXJ;><#@4%GN7?U0:?9;[T6#3'H-T>MU_BTU8*G_->=$WYLK )I9&=A%+C6;G:ZKQOM MYFCT&GX?]K&#=G/:O4ZM M ?^543Z$I_W::WI>11DT::DFQ>'A4V*?B&YC\&#G";N86"4#HG3ZFA&<4&4+ M>"U*]N;) LN?UA8TPAX>_"H\6LZM1;[- M7W&#CJA!"QUU?H]_'38JQU]\TQM.!S4!H,1ZG/0IFV$4/!['Q1^ MR24T\+S3&]?Z,%@7="RV[_=;T+XW'M2J;Z2!QKU>&QH/@,!Q?3SJU'KU5K]= M&X L;->,^Z?V< Y.KS[H#- 35Q]W1C1_(!>1R1"()\]B'BWXZ 0 M17$34ZQXI8Y.=! 3])H+O*!-7,($;$%5Q@=MI.&IF'^XO;VD(O+))5A*%S=W M5USD9.H4]NZP"\@2*%!=J9+I2?2'X)9GU2:"R3G;M4 M*2+LT_)U^(QH]S[_JH2XL]@CP-I[D4;W?0U;O M =0=T*D> Z_3<6_5QXBWKZ83\FW#!K2&L#D=.(+C<0\.1VO8JE$940W0=Z,V M&L"/_B#U8\,Y'/9HC#&@:#A6G?J !NNTZL,6/@%@WAH-BSJ3TZ%<9-BC>3:QASNL#RP?/9_.SF ][Z>7TN M9O/Y![H][NQFOIA3KHA*-BW"=TD:CC+V? KD/DBVAI-BV]2SG;@DDCGK]) + M]LFJ D/.,78E@RM?V('U*.(=_OJJW<)X5:NYGRH[D(_B5:>/375=BU0]YHOE M;%4II:]YH=$8TN(5QR@G7@VY)\P'F\:AR? MBMG5[61VAT@3->+%;'IY3A[Z6_K(5!J)M*6,D M?>7O/@W@M)@92][VD^EIG MU-VB#$?T+R;Z29C Z4P^*E614DM\3YUQ=C_SU0)<-CVG0NSRZFE?J0%,Y4RK M"!.VME2A\J&^,RX4DIO0RDPNR8YJ>&1UMF*5%=D45TG)OW&G! N*2GJPP)V\ M,)Q%P17/SPN)1=G=Y#P;%%DI:U%FJ)J@6B$]'3J9.M2L9#%?F.2O5IR:N7<" MN7MFQ,E*)TQP_CO?6N0KUR*ZR]?JOJ!L)L^@WL.<[S2YS;(?N+9_Y:>EO:8O MD[/-T^3 ) ^6_+>>C355%-H$2Z*3!APPLQN7";W>P =U0WJ0S,I:TEDVLWVZ M4SI2OF*55YW<[T:E;CK-UO),^964!QB[ O,(ULEE 1S*^+QK/<3)K:J;+5P< M=FP-ZE%W=[P4M+X4M+X4M+X4M+X4M+X4M+X4M+X4M+X4M+X4M+X4M+X4M+X4 MM+X4M+X4M+X4M+X4M+X4M+X4M/[?+&@URPE/%G1U>_%;"I8;T-",)_9\?>5+ M9>+_FLK$TM*1H_:WF"M9^.Z#EUSY_[^Y\OM8YP+3BG_6:<6*!=DG-&%7R ?2 MBMDD8LUJ*HGX"B'G45&+ETSFETSF+\ADWL?)USJWV?RRK8Q;=*HB&7MU9W M1@:TD91^1QG096OUDC[]+Y ^77Y;$.A(XYLK,Z?J7((][(9OCOX>-[-;2K7& M.Q84]#*N'JI.+9N6W8;C'_L]3J;)UQ 5=N)G3"MC/Q6^P3=G/N6?%RRHS[NW MY6MN$WTS'MK7=*GKYAXCOJKH M4?Q=[%^.S"4M1[#PWF^M?"7>JKK2\N\PS0ZVGZ/9@ZFVI+IZ@OI3EVBN:[^A*;X]X]SK/UA7Q>/G,T3X^_Y@BI5=^N\T[- M2>028NB2C[VG),>))?=7E)_!E&E)S)5]AWIRVT7Y:4JN]$9)OW.-;0@[T M8R>I,++K^##>KBD-,/3E@YNY3TI;R!SWDE<10^YZ4* M'^)SNLA-6VG[SYASBQP!XA>ZCWE"F^H!.33;Z@ MFVK&^8).BZST=1:NG+.^H,/]O%;=\3%2ZNLYP_?HL(.QFE+G:K[10-W\U%4. MN V/./VV5+73_^.W.-R$'_+%3 M+A+3*]GU(XY4SBM? L*45SX\VBW_&:;\<2[7HLN!+4?MYRO6\VBO\WG.ZWRF MONWX/$B[V\!_Y(#^#.7,P+E+K-9.(4N%A[*666V%*R!(WJT*U]3Y> M613O@:B+Y!KT<@.F7VZ_T"B8X\+#*V]DQM@ND?)C7J.,ONIGWW^50-"_+%-Y%>DE# MJ&]I*&K<$J!RF^8/T@4/@")+:KY;9=C@/$XS2JLO*JCB_]HWW^"%!86)!%QV MPE_DK;+B\HU^TC< E,HJEN&$"B>E\G&1J>#//S6$@"U7DM)ZL[7\1:<\IM+^ M4N+9[);MU9S+FXOYCQ%R!Z(RU+TL4UH_X%"HSSX@ M=-@GEGC%WE=5:.>)_KLXA#$F7Z'T.NWS;1A&W_\W4$L! A0#% @ )C)B M28Z.GY&Q 0 A8 !, ( ! %M#;VYT96YT7U1Y<&5S M72YX;6Q02P$"% ,4 " F,F))2'4%[L4 K @ "P M@ 'B 0 7W)E;',O+G)E;'-02P$"% ,4 " F,F))KJYLJ'\! #P% M&@ @ '0 @ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " F,F))R4>(DJ4" #$"0 $ @ &'! M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( "8R8DGMJS]@/@$ &D# 1 M " 5H' !D;V-0&UL4$L! A0#% @ )C)B22L6QE&PO=V]R:V)O;VLN>&UL4$L! A0# M% @ )C)B2<^;F@!. @ ] < !@ ( !&14 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ )C)B2=:'N-F M! \A, !@ ( !'AX 'AL+W=OP( (X( 8 " M =0B !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ )C)B2=7:A#:_ 0 600 !@ M ( !GRP 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ )C)B2>NN9H>? 0 L0, !D ( !=3< 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ )C)B20AA M'U^= 0 L0, !D ( !^3P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ )C)B21YD\2V@ 0 L0, !D M ( !>T( 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ )C)B2:ED!6:C 0 L0, !D ( ! M!4@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ )C)B21L?R(>W 0 0P0 !D ( !MTT 'AL+W=O&UL4$L! A0#% @ )C)B27.& ZR' M @ Z0D !D ( !,E0 'AL+W=O&PO=V]R:W-H965TK0( '\) 9 " 2]9 !X;"]W;W)K&UL4$L! A0#% @ )C)B25K?'+J6 @ J@H !D M ( !$UP 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ )C)B2?0G['.Y @ 0@H !D ( !<&0 M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M)C)B22EDWS1J) HY\ !0 ( !AVP 'AL+W-H87)E9%-T ?&UL4$L%!@ J "H 6 L ".1 $! end XML 47 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 109 170 1 true 32 0 false 4 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.novocure.com/20160930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDBALANCESHEETS CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 100020 - Statement - CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 100040 - Statement - CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONSOLIDATEDINTERIMSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 100050 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONDENSEDINTERIMSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 100060 - Statement - CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONDENSEDINTERIMSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITYParenthetical CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) Statements 7 false false R8.htm 100070 - Statement - CONDENSED INTERIM CONSOLIDATED CASH FLOWS Sheet http://www.novocure.com/20160930/taxonomy/role/StatementCONDENSEDINTERIMCONSOLIDATEDCASHFLOWS CONDENSED INTERIM CONSOLIDATED CASH FLOWS Statements 8 false false R9.htm 100080 - Disclosure - Organization and Basis of Presentation Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentation Organization and Basis of Presentation Notes 9 false false R10.htm 100090 - Disclosure - Short-Term Investments Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureShortTermInvestments Short-Term Investments Notes 10 false false R11.htm 100100 - Disclosure - Inventories Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureInventories Inventories Notes 11 false false R12.htm 100110 - Disclosure - Commitments and Contingent Liabilities Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureCommitmentsAndContingentLiabilities Commitments and Contingent Liabilities Notes 12 false false R13.htm 100120 - Disclosure - Share Capital Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureShareCapital Share Capital Notes 13 false false R14.htm 100130 - Disclosure - Equity Incentive Plan Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlan Equity Incentive Plan Notes 14 false false R15.htm 100140 - Disclosure - Supplemental Information Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureSupplementalInformation Supplemental Information Notes 15 false false R16.htm 100150 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureLongTermLoanNetOfDiscountAndIssuanceCosts Long-Term Loan, Net of Discount and Issuance Costs Notes 16 false false R17.htm 100160 - Disclosure - Impairment of Field Equipment Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureImpairmentOfFieldEquipment Impairment of Field Equipment Notes 17 false false R18.htm 100170 - Disclosure - Organization and Basis of Presentation (Policies) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureOrganizationAndBasisOfPresentationPolicies Organization and Basis of Presentation (Policies) Policies 18 false false R19.htm 100180 - Disclosure - Inventories (Tables) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.novocure.com/20160930/taxonomy/role/DisclosureInventories 19 false false R20.htm 100190 - Disclosure - Equity Incentive Plan (Tables) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlanTables Equity Incentive Plan (Tables) Tables http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlan 20 false false R21.htm 100200 - Disclosure - Supplemental Information (Tables) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureSupplementalInformationTables Supplemental Information (Tables) Tables http://www.novocure.com/20160930/taxonomy/role/DisclosureSupplementalInformation 21 false false R22.htm 100210 - Disclosure - Short-Term Investments - Additional Information (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureShortTermInvestmentsAdditionalInformationDetails Short-Term Investments - Additional Information (Details) Details 22 false false R23.htm 100220 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 23 false false R24.htm 100230 - Disclosure - Commitments and Contingent Liabilities - Additional Information (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureCommitmentsAndContingentLiabilitiesAdditionalInformationDetails Commitments and Contingent Liabilities - Additional Information (Details) Details 24 false false R25.htm 100240 - Disclosure - Share Capital - Additional Information (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureShareCapitalAdditionalInformationDetails Share Capital - Additional Information (Details) Details 25 false false R26.htm 100250 - Disclosure - Equity Incentive Plan - Additional Information (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlanAdditionalInformationDetails Equity Incentive Plan - Additional Information (Details) Details 26 false false R27.htm 100260 - Disclosure - Equity Incentive Plan - Schedule of Stock Option Plan (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfStockOptionPlanDetails Equity Incentive Plan - Schedule of Stock Option Plan (Details) Details 27 false false R28.htm 100270 - Disclosure - Equity Incentive Plan - Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfFairValueOfEquityBasedAwardsUsingBlackScholesOptionPricingModelDetails Equity Incentive Plan - Schedule of Fair Value of Equity Based Awards Using Black-Scholes Option Pricing Model (Details) Details 28 false false R29.htm 100280 - Disclosure - Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureEquityIncentivePlanScheduleOfNonCashShareBasedCompensationExpensesRelatedToCompanySEquityBasedAwardsDetails Equity Incentive Plan - Schedule of Non-cash Share-Based Compensation Expenses Related to Company's Equity-Based Awards (Details) Details 29 false false R30.htm 100290 - Disclosure - Supplemental Information - Schedule of Long-Lived Assets by Location (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureSupplementalInformationScheduleOfLongLivedAssetsByLocationDetails Supplemental Information - Schedule of Long-Lived Assets by Location (Details) Details 30 false false R31.htm 100300 - Disclosure - Supplemental Information - Schedule of Revenues by Geographic Region (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureSupplementalInformationScheduleOfRevenuesByGeographicRegionDetails Supplemental Information - Schedule of Revenues by Geographic Region (Details) Details 31 false false R32.htm 100310 - Disclosure - Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureLongTermLoanNetOfDiscountAndIssuanceCostsAdditionalInformationDetails Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) Details 32 false false R33.htm 100320 - Disclosure - Impairment of Field Equipment - Additional Information (Details) Sheet http://www.novocure.com/20160930/taxonomy/role/DisclosureImpairmentOfFieldEquipmentAdditionalInformationDetails Impairment of Field Equipment - Additional Information (Details) Details 33 false false All Reports Book All Reports nvcr-20160930.xml nvcr-20160930.xsd nvcr-20160930_cal.xml nvcr-20160930_def.xml nvcr-20160930_lab.xml nvcr-20160930_pre.xml true true ZIP 52 0001564590-16-026833-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-16-026833-xbrl.zip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end

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 27, 2016
Document Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	NVCR
Entity Registrant Name	Novocure Ltd
Entity Central Index Key	0001645113
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		86,780,413

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 115,822	$ 119,423
Short-term investments	119,724	150,001
Restricted cash	72	87
Receivables and prepaid expenses	11,840	10,799
Inventories	23,972	13,594
Total current assets	271,430	293,904
LONG-TERM ASSETS:
Property and equipment, net	9,886	6,552
Field equipment, net	8,042	6,029
Severance pay fund	89	79
Other long-term assets	1,646	772
Total long-term assets	19,663	13,432
TOTAL ASSETS	291,093	307,336
CURRENT LIABILITIES:
Trade payables	15,243	16,755
Other payables and accrued expenses	14,469	11,872
Total current liabilities	29,712	28,627
LONG-TERM LIABILITIES:
Long-term loan, net of discount and issuance costs	95,970	23,097
Employee benefit liabilities	3,132	2,057
Other long-term liabilities	4,036	2,735
Total long-term liabilities	103,138	27,889
TOTAL LIABILITIES	132,850	56,516
COMMITMENTS AND CONTINGENCIES	0	0
SHAREHOLDERS' EQUITY:
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,775,203 (unaudited) shares and 83,778,581 shares at September 30, 2016 and December 31, 2015, respectively	0	0
Additional paid-in capital	658,086	640,406
Accumulated other comprehensive loss	(2,085)	(1,505)
Accumulated deficit	(497,758)	(388,081)
Total shareholders' equity	158,243	250,820
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 291,093	$ 307,336

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0	$ 0
Common stock, shares authorized	Unlimited	Unlimited
Common stock, shares issued	85,775,203	83,778,581
Common stock, shares outstanding	85,775,203	83,778,581

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Income Statement [Abstract]
Net revenues	$ 21,674	$ 8,953	$ 52,646	$ 20,704	$ 33,087
Cost of revenues	11,118	5,659	28,897	14,306	20,610
Impairment of field equipment			6,412
Gross profit	10,556	3,294	17,337	6,398	12,477
Operating costs and expenses:
Research, development and clinical trials	10,233	10,211	32,996	32,903	43,748
Sales and marketing	15,865	8,916	43,771	24,137	38,861
General and administrative	12,723	8,405	38,010	22,748	33,864
Total operating costs and expenses	38,821	27,532	114,777	79,788	116,473
Operating loss	(28,265)	(24,238)	(97,440)	(73,390)	(103,996)
Financial expenses, net	2,189	809	3,293	2,277	3,151
Loss before income tax expense	(30,454)	(25,047)	(100,733)	(75,667)	(107,147)
Income tax expense	3,174	976	8,944	2,986	4,434
Net loss	$ (33,628)	$ (26,023)	$ (109,677)	$ (78,653)	$ (111,581)
Basic and diluted net loss per ordinary share	$ (0.39)	$ (2.09)	$ (1.29)	$ (6.21)	$ (3.67)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	85,774,874	12,431,586	85,153,644	12,666,455	30,401,603

CONDENSED INTERIM STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY(Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Series J Preferred Stock
Share issuance expenses	$ 319
Over-Allotment
Share issuance expenses	$ 15,742

Organization and Basis of Presentation	9 Months Ended
Organization and Basis of Presentation	Sep. 30, 2016
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1: ORGANIZATION AND BASIS OF PRESENTATION Organization. NovoCure Limited (including its consolidated subsidiaries, the “Company”) was incorporated in the Bailiwick of Jersey and is principally engaged in the development, manufacture and commercialization of TTFields for the treatment of solid tumors. Since inception, the Company has devoted substantially all of its efforts to developing and commercializing a family of products to deliver TTFields for a variety of solid tumor indications, raising capital and recruiting personnel. The Company has regulatory approvals and clearances in certain countries for Optune, its first TTFields delivery system, to treat glioblastoma (“GBM”). The Company commenced marketing Optune in the United States at the end of 2011, in certain countries in Europe in 2014 and in Japan in 2015. Financial statement preparation. The accompanying condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries, and intercompany accounts and transactions have been eliminated. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. These condensed consolidated financial statements and accompanying notes should be read in conjunction with the Company’s annual consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (the “2015 10-K”) filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2016. The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the 2015 10-K are applied consistently in these unaudited interim consolidated financial statements. Recently Issued Accounting Pronouncements. In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02-Leases (ASC 842), which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of their classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840. The standard is effective on January 1, 2019, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In March 2016, FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements. In April 2016, FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. ASU 2016-10 covers two specific topics: performance obligations and licensing. This amendment includes guidance on immaterial promised goods or services, shipping or handling activities, separately identifiable performance obligations, functional or symbolic intellectual property licenses, sales-based and usage-based royalties, license restrictions (time, use, geographical) and licensing renewals. In addition, in May 2016, FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The Company is currently evaluating the impact of the adoption of both revenue standards on its consolidated financial statements. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 amends the impairment model to utilize an expected loss methodology in place of the currently used incurred loss methodology, which will result in the more timely recognition of losses. ASU 2016-13 also applies to employee benefit plan accounting, with an effective date of the first quarter of fiscal 2022. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements and employee benefit plans’ accounting. In August 2016, FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 eliminates the diversity in practice related to the classification of certain cash receipts and payments for debt prepayment or extinguishment costs, the maturing of a zero coupon bond, the settlement of contingent liabilities arising from a business combination, proceeds from insurance settlements, distributions from certain equity method investees and beneficial interests obtained in a financial asset securitization. ASU 2016-15 designates the appropriate cash flow classification, including requirements to allocate certain components of these cash receipts and payments among operating, investing and financing activities. The retrospective transition method, requiring adjustment to all comparative periods presented, is required unless it is impracticable for some of the amendments, in which case those amendments would be prospectively adjusted as of the earliest date practicable. The standard is effective on January 1, 2019. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

Short-Term Investments	9 Months Ended
Short-Term Investments	Sep. 30, 2016
Marketable Securities Current [Abstract]
Short-Term Investments	NOTE 2: SHORT-TERM INVESTMENTS The Company invests in marketable U.S. Treasury Bills (“T-bills”) that are classified as held-to-maturity securities. The amortized cost and recorded basis of the T-bills are presented as short-term investments in the amount of $119,724 and $150,001 as of September 30, 2016 and December 31, 2015, respectively, and their estimated fair value as of September 30, 2016 and December 31, 2015 was $119,604 and $149,978, respectively.

Commitments and Contingent Liabilities	9 Months Ended
Commitments and Contingent Liabilities	Sep. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 4: COMMITMENTS AND CONTINGENT LIABILITIES The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024. The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019. As of September 30, 2016 and December 31, 2015, the Company pledged bank deposits of $807 and $133, respectively, to cover bank guarantees in respect of its leases of operating facilities and obtained guarantees by the bank for the fulfillment of the Company’s lease commitments of $962 and $283, respectively.

Share Capital	9 Months Ended
Share Capital	Sep. 30, 2016
Share Based Compensation Allocation And Classification In Financial Statements [Abstract]
Share Capital	NOTE 5: SHARE CAPITAL For the nine months ended September 30, 2016, warrants to purchase 220,316 ordinary shares with an exercise price of $3.59 were exercised, resulting in the issuance of 220,316 ordinary shares, and warrants to purchase 975,644 and 888,219 ordinary shares with exercise prices of $18.09 and $3.59 per share, respectively, were cashlessly exercised, resulting in the issuance of 950,637 ordinary shares. For the nine months ended September 30, 2016, options to purchase 825,240 ordinary shares were exercised for cash and options to purchase 3,547 ordinary shares were cashlessly exercised, resulting in the issuance of 825,669 ordinary shares. For additional information on option exercises, please see Note 6.

Long-Term Loan, Net of Discount and Issuance Costs	9 Months Ended
Long-Term Loan, Net of Discount and Issuance Costs	Sep. 30, 2016
Debt Disclosure [Abstract]
Long-Term Loan, Net of Discount and Issuance Costs	NOTE 8: LONG-TERM LOAN, NET OF DISCOUNT AND ISSUANCE COSTS In January 2015, the Company entered into a five-year term loan agreement (the “Term Loan Credit Facility”) with a lender to draw up to $100,000. In January 2015, the Company drew $25,000 from the lender. The Company had the option to draw the remaining $75,000 at its option at any time through June 30, 2016. On June 30, 2016, the Company provided to the lender a drawdown notice for the remaining $75,000, and it received funds in July 2016. As of September 30, 2016, there is $100,000 outstanding under the Term Loan Credit Facility. Interest on the outstanding loan is 10% annually, payable quarterly in arrears. In addition, there is a 1.5% funding fee payable on the amount drawn on the funding date, a 0.75% pay-down fee on all principal amount repayments to be paid on the date such payments of principal are made and a pre-payment fee of 3.0%, 2.0% or 1.0% if the Company prepays outstanding loan amounts prior to the first, second or third year anniversaries, respectively, from the initial funding date. The entire outstanding principal loan is due in January 2020. The loan is secured by a first priority security interest in substantially all assets of the Company. The Term Loan Credit Facility sets forth certain affirmative and negative covenants with which the Company must comply on a quarterly basis through the term of the loan. As of September 30, 2016, the Company was in compliance with such covenants. The total discount of $2,019 and additional issuance costs of $2,744 are presented net of the loan and are amortized to interest expense over the term of the loan using the effective interest method.

Impairment of Field Equipment	9 Months Ended
Impairment of Field Equipment	Sep. 30, 2016
Impairment Or Disposal Of Tangible Assets Disclosure [Abstract]
Impairment of Field Equipment	NOTE 9: IMPAIRMENT OF FIELD EQUIPMENT The Company received U.S. Food and Drug Administration approval on its Premarket Approval supplement application to market its second generation Optune System in the United States on July 13, 2016. The Company made the second generation Optune System available to all patients in the United States during the quarter ended September 30, 2016. Manufacturing of the first generation Optune System has been terminated. For the nine months ended September 30, 2016, the Company recorded an impairment loss in the second quarter with respect to the write-off of first generation Optune System field equipment (finished goods and production stage) in the amount of $6,412, including advances for materials purchased and liabilities incurred to vendors of $1,582 that are not recoverable, presented in cost of revenues. The Company does not expect the conversion to result in an additional material impairment charge in the future.

Short-Term Investments - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Short-term investments	$ 119,724	$ 150,001
Estimated fair value of short-term investments	$ 119,604	$ 149,978

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 4,517	$ 3,518
Work in progress	9,621	4,618
Finished products	9,834	5,458
Total	$ 23,972	$ 13,594

Commitments and Contingent Liabilities - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Loss Contingencies [Line Items]
Operating lease expiration description	The facilities of the Company are leased under various operating lease agreements for periods ending no later than 2024.
Pledged bank deposits	$ 807	$ 133
Operating Lease Commitments	$ 962	$ 283
Motor Vehicles
Loss Contingencies [Line Items]
Operating lease expiration description	The Company also leases motor vehicles under various operating leases, which expire on various dates, the latest of which is in 2019.
Maximum
Loss Contingencies [Line Items]
Operating lease agreements, expiration year	2024
Maximum \| Motor Vehicles
Loss Contingencies [Line Items]
Operating lease agreements, expiration year	2019

Share Capital - Additional Information (Details)	9 Months Ended
Share Capital - Additional Information (Details)	Sep. 30, 2016 $ / shares shares
Share Capital [Line Items]
Options issued to purchase ordinary shares exercised for cash	825,240
Options issued to purchase ordinary shares cashlessly exercised	3,547
Ordinary shares issued upon option exercise	825,669
Warrants to Purchase 220,316 Ordinary Shares
Share Capital [Line Items]
Warrants issued to purchase of ordinary shares	220,316
Warrants exercise price \| $ / shares	$ 3.59
Warrants exercised to ordinary shares	220,316
Warrants to Purchase 975,644 Ordinary Shares
Share Capital [Line Items]
Warrants issued to purchase of ordinary shares	975,644
Warrants exercise price \| $ / shares	$ 18.09
Warrants to Purchase 888,219 Ordinary Shares
Share Capital [Line Items]
Warrants issued to purchase of ordinary shares	888,219
Warrants exercise price \| $ / shares	$ 3.59
Warrant
Share Capital [Line Items]
Warrants exercised to ordinary shares	950,637

Equity Incentive Plan - Additional Information (Details)	9 Months Ended
	Sep. 30, 2016 shares
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Ordinary shares available for grants	1,667,785
Shares issued under plan	0
2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Option granted vesting period	4 years
Option granted expiration period	10 years
Ordinary shares available for grants	12,717,460

Equity Incentive Plan - Schedule of Stock Option Plan (Details)	9 Months Ended
	Sep. 30, 2016 $ / shares shares
Number of options
Number of options, Outstanding at beginning of year \| shares	10,134,829
Number of options, Granted \| shares	2,363,575
Number of options, Exercised \| shares	(828,787)
Number of options, Forfeited and cancelled \| shares	(133,364)
Number of options, Outstanding at ending of year \| shares	11,536,253
Number of options, Exercisable options \| shares	5,887,411
Number of options, Vested and expected to vest \| shares	11,329,415
Weighted average exercise price
Weighted average exercise price, Outstanding at beginning of year \| $ / shares	$ 8.20
Weighted average exercise price, Granted \| $ / shares	13.61
Weighted average exercise price, Exercised \| $ / shares	0.24
Weighted average exercise price, Forfeited and cancelled \| $ / shares	17.19
Weighted average exercise price, Outstanding at end of year \| $ / shares	9.78
Weighted average exercise price, Exercisable options \| $ / shares	5.05
Weighted average exercise price, Vested and expected to vest \| $ / shares	$ 9.71

Supplemental Information - Schedule of Long-Lived Assets by Location (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 17,928	$ 12,581
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	11,792	6,600
Switzerland
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	3,769	4,204
Israel
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	1,934	1,376
Others
Revenues From External Customers And Long Lived Assets [Line Items]
Long-lived assets	$ 433	$ 401

Long-Term Loan, Net of Discount and Issuance Costs - Additional Information (Details) - Term Loan - USD ($)	1 Months Ended	9 Months Ended
	Jan. 31, 2015	Sep. 30, 2016	Jun. 30, 2016
Line Of Credit Facility [Line Items]
Term loan agreement, maturity period	5 years
Line of credit facility, maximum borrowing capacity	$ 100,000,000
Line of credit facility, current borrowing capacity	$ 25,000,000
Line of credit facility, remaining borrowing capacity			$ 75,000,000
Line of credit facility, drawdown received date		2016-07
Term loan credit facility, outstanding		$ 100,000,000
Interest on the outstanding loan		10.00%
Funding fees payable		1.50%
Prepayment fee percent		0.75%
Due date of outstanding principal loan		Jan. 31, 2020
Frequency of payments		Quarterly
Other Long-term Assets
Line Of Credit Facility [Line Items]
Total discount		$ 2,019,000
Additional deferred issuance costs		$ 2,744,000
First Year
Line Of Credit Facility [Line Items]
Prepayment fee percent		3.00%
Second Year
Line Of Credit Facility [Line Items]
Prepayment fee percent		2.00%
Third Year
Line Of Credit Facility [Line Items]
Prepayment fee percent		1.00%

Impairment of Field Equipment - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($)
Impaired Long Lived Assets Held And Used [Line Items]
Impairment of field equipment	$ 6,412
First Generation Optune System Field Equipment \| Cost of Revenues
Impaired Long Lived Assets Held And Used [Line Items]
Impairment of field equipment	6,412
Advances for materials purchased and liabilities incurred to vendors	$ 1,582